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Caspase-4 is a human caspase without an obvious corresponding mouse 
homologue. Based on sequence homology and gene positioning in the cluster of 
caspases located on human chromosome 11 compared to mouse chromosome 9, 
caspase-4 might be a functional homologue of either mouse caspase-12 or mouse 
caspase-11, with which it shares the most homology. Like caspase-12, I found that 
caspase-4 is processed in response to endoplasmic reticulum (ER) stress. Using a 
neuroblastoma cell line stably expressing short hairpin (shRNA) against caspase-4, I 
show that caspase-4 is not required for cell death induced by many stimuli, but 
contributes only to endoplasmic reticulum stress induced by tunicamycin, 
thapsigargin, Brefeldin A and the calcium ionophore A23187. Moreover, caspase-4 is 
localized predominantly in the ER. An expansion of polyglutamine tracts is an 
underlying mutational mechanism of several neurodegenerative diseases; and 
aggregates or deposits of polyglutamine [poly(Q)] protein are a prominent 
pathological characteristic of most polyglutamine diseases. Evidence suggests that an 
expanded poly(Q) tract exists in an abnormal conformation, and this mis-folded 
protein might trigger an ‘unfolded protein response’ in the classical ER stress 
pathway. Here I show that poly(Q)72 aggregates (but not the nontoxic poly(Q)11) 
induce ER stress. Caspase-4 is also cleaved in the presence of poly(Q)72 aggregates, 
and polyglutamine-induced apoptosis is significantly reduced in the clones stably 
expressing shRNA against caspase-4. Longer Poly(Q) aggregates may therefore 
manifest pathology in neurodegenerative diseases through ER stress, and hence I 
speculate that caspase-4 may have a role in the pathogenesis of well-known disorders 
 xii
caused by expansion of an unstable CAG triplet (e.g. SBMA, Huntington’s, DRPLA, 
and SCA-1,-2, -3,- 6, and - 7).  
Caspase-4 also falls within the class of "inflammatory caspases", being the 
closest homologue of mouse caspase-11. To address the function of caspase-4, I 
generated stable caspase-4-deficient human THP1 monocytic cell lines, which 
exhibited substantially reduced LPS-induced secretion of several chemokines and 
cytokines, including IL-8, MIP-1β, MIP-3α and IL-1β. The LPS-induced expression 
of the mRNAs encoding these cytokines was correspondingly reduced in the caspase-
4-deficient clones. Since a specific NF-κB inhibitor blocked LPS-induced IL-8 and 
MIP-1β mRNA expression as well as IL-8 and MIP-1β secretion in THP1 cells, I 
investigated the role of caspase-4 in NF-κB signaling. LPS-induced NF-κB nuclear 
translocation and activation were inhibited in all caspase-4-deficient clones. LPS 
stimulated endogenous caspase-4 and TRAF6 to interact; likewise, transfected 
caspase-4 (but not caspase-1) interacted with exogenous TRAF6. Mutation of a 
TRAF6-binding motif (PPESGE) that I identified in caspase-4 resulted in loss of the 
TRAF6-caspase-4 interaction. Similar motifs are known to be functionally important 
for TRAF6 interactions with other molecules, and for mediating NF-κB activation in 
various immune and non-immune cell types. I therefore speculate that the TRAF6-
caspase-4 interaction, triggered by LPS, leads to NF-κB-dependent transcriptional up-
regulation and secretion of important cytokines in innate immune signaling in human 
monocytic cells. 
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1. CHAPTER 1. Introduction 
 
 
This chapter commences with a general introduction of caspases, which in due 
course leads to a focus on caspase-4. Caspases can function in two divergent 
pathways viz., apoptosis and inflammation. Hence, I follow it up with an exploration 
of these two topics. On apoptosis, the issues covered include the types of apoptosis 
and the signaling mechanisms involving different caspases, with examples from 
classical methods. With inflammation, the emphasis will be on innate immunity with 
a special focus on LPS-mediated signaling, as this pathway involves a few caspases. I 
will highlight the key players in these signaling schemes before concluding this 
chapter by discussing the rationale of this thesis. 
 
1.1 Caspases 
Caspases are proteases with principal roles in apoptosis and inflammation. 
Their central role in these processes makes them attractive drug targets for treating 
cancer, stroke, heart attack, arthritis, Alzheimer's and autoimmune diseases. 
Historically, the identification of cell death genes (ced-3) in the nematode 
Caenorhabditis elegans (Yuan et al., 1993; Miura et al., 1993) with its similarity to 
interleukin-1β converting enzyme /ICE (Thornberry et al., 1992; Cerretti et al., 1992) 
and Nedd2/Caspase-2 (Kumar et al., 1992; Kumar et al., 1994) led to the 
characterization of its mammalian homologues. There are eleven human, ten mouse, 
four chicken, four zebrafish, seven Drosophila and four C.elegans caspases 
(Lamkanfi et al., 2002). 
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Figure 1.1 Caspase structure and activation. 
Schematic of the full length pro-form of the caspase zymogen and the active caspase. After 
self or induced activation and proteolysis, the p20 and p10 subunits together homodimerize 
with a corresponding heterodimer to generate the active heterotetramer.  
Caspases are highly conserved across the evolutionary tree with respect to 
amino acid sequence, structure, and substrate specificity. They are synthesized as 
zymogens composed of three domains viz., a variable length N-terminal prodomain, a 
p20 large subunit and a p10 small subunit (Figure 1.1).  
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These cysteine proteases have a primary specificity for aspartic acid (Asp) and 
cleave their substrates after tetrapeptide motifs that contain Asp in the P1 position 
(Cohen, 1997; Earnshaw et al., 1999). These inactive procaspases are activated by 
proteolysis at the internal Asp residue either by autoprocessing or by other initiator 
caspases. Generally, the mature enzyme is a heterotetramer containing two p20/p10 
heterodimers and two catalytic active sites (Figure 1.1). In the normal state, cells have 
a complement of caspases present as zymogens that are kept in check by various 
regulatory molecules (Kumar, 2007). Upon receipt of the activating signal, caspases 
are activated in a highly regulated signaling scheme resulting in a caspase cascade 
that culminates in specific cleavage of cellular proteins. 
1.1.1 Functional classification of caspases 
 
Caspases can be functionally classified into two broad groups viz., apoptotic 
caspases and inflammatory caspases. The mammalian and mouse apoptotic group 
comprises caspases 2, 6, 7, 8, 9 and 10, while the inflammatory group includes 
caspases 1, 4, and 5 in mammals and caspases 1, 11, and 12 in mouse. Caspase-14 is 
involved in differentiation of keratinocytes (Eckhart et al., 2000; Lippens et al., 2000) 
and hence does not fall under any of these two categories. This classification does not 
imply a clear demarcation of the function of these caspases as many of them have 
been found recently to have dual functions in apoptosis as well as in diverse signaling 
mechanisms like survival, proliferation and differentiation (Lamkanfi et al., 2007). In 
mammals, these range from inflammation - caspases 1, 5, 11, 12 (Li et al., 1995; 
Martinon et al., 2002; Saleh et al., 2006; Wang et al., 1998); cell differentiation - 
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caspases 3, 8, 14 (Black et al., 2004; Eckhart et al., 2000; Fernando et al., 2002; 
Fernando et al., 2005; Kang et al., 2004; Miura et al., 1993; Sordet et al., 2002; Zandy 
et al., 2005; Zermati et al., 2001); proliferation and suppression of immune cell 
development - caspases 8 and 3, respectively (Beisner et al., 2005; Chun et al., 2002; 
Salmena et al., 2003; Santambrogio et al., 2005; Woo et al., 2003); and NF-κB 
activation - caspases 1, 2, 8, 10 (Lamkanfi et al., 2004; Lamkanfi et al., 2006; Su et 
al., 2005; Varfolomeev et al., 2005; Chaudhary et al., 2000; Takahashi et al., 2006; 
Lamkanfi et al., 2005). Some of the non-apoptotic roles are evolutionarily conserved; 
for example, the Drosophila caspase DREDD has a prominent role in innate 
immunity (Leulier et al., 2000). Perhaps it is not surprising that a single protein can 
play multiple roles, given the advanced complexity in humans achieved with 
proportionally fewer genes (up to around 25,000) compared to lower organisms, some 
of which have significantly more number of genes than humans (National human 
genome research institute news release, 2004). 
 
1.2 Caspase-4  
1.2.1 History 
 
In 1995, Caspase-4 was cloned by three groups (Kamens et al., 1995; Faucheu 
et al., 1995; Munday et al., 1995) as ICE homology protein 2 (ICH-2), TX and 
ICErelII, respectively from human monocytic cells with 52% homology to caspase-1. 
It has the characteristic active site with the pentapeptide, QACRG (Figure 1.2), found 
to be synthesized as a large prodomain with a long CARD domain; and induces 
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apoptosis upon overexpression. This caspase cleaves and activates its own as well as 
caspase-1 precursor proteins. Nevertheless, it does not possess IL-1β converting 
enzyme activity, unlike caspase-1.  
 
Figure 1.2 Caspase-4 predicted structure. Caspase-4 structure predicted based on 
SwissProt modeling. Protein modeling by email  (Guex and Peitsch, 1997; Peitsch et al., 
1995; Schwede et al., 2003) The conserved pentapeptide containing the catalytic cysteine of 
caspase-4, QACRG are depicted as green, red, blue, yellow, pink residues respectively. 
 
1.2.2 Chromosomal position of casp-4 gene in the human genome 
 
Casp-4 is located on human chromosome-11 at the coordinates: 11q22.2 – 
q22.3. The introns and exons of this gene span a region of 25,700 bp at this locus. 
Caspase-4 is encoded by nine exons interspersed by 10 intron regions (Figure 1.3), 
Alternative splicing of the casp-4 gene results in three transcript variants encoding 
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distinct isoforms viz., alpha, gamma and delta. Isoform alpha encodes the longest 
isoform. The isoform gamma contains a unique 5’ end fragment and lacks the 
translation start codon used by isoform alpha. Translation begins at a downstream in-
frame start codon, and results in an N-terminally truncated protein. Transcript isoform 
delta contains a unique internal fragment absent in alpha, which leads to a translation 
frameshift. Two polypeptides are produced from this isoform. One corresponds to the 
N-terminal portion of isoform alpha and has a distinct C-terminus; while another is 




1                                                               25.7KbhChrom 11
α
13.5 Kb                        2.7      0.7   1.1    0.8     1.3        2.2       1.77
48                                     255        110  174    234   144    110         103       105  
γ
δ
11.9 Kb          1.6         2.7      0.7   1.1 0.8     1.3        2.2       1.77
102     255        110  174    234  144    110         103       105  
13.5 Kb                       2.6      0.7   1.1    0.8     1.3        2.2       1.77
48                                    255        167  174    234   144    110         103       105  
 
 
Figure 1.3 Organization of casp-4 on human chromosome 11. 
The three major mRNAs (α,γ,δ) transcribed from this region are shown with their exons 





For nearly a decade, nothing was known about caspase-4 as it does not have 
an exact mouse homologue. Caspase-4 has 59% homology to caspase-11 and 48% 
homology to caspase-12. In 2004, caspase-4 was shown to have a role in endoplasmic 
reticulum stress-mediated apoptosis (Hitomi et al., 2004), where caspase-4 was 
shown to localize to the ER and participate in ER stress-induced apoptosis and 
amyloid beta (Aβ)-induced apoptosis. This was disputed (Obeng and Boise, 2005) in 
studies using cell lines lacking the expression of caspase-4 and using a putative 
caspase-4 fluorogenic substrate, LEVD-AFC. It is possible that the role of caspase-4 
in ER stress-induced apoptosis is cell line specific (Hitomi et al., 2004). 
Later on, the role of caspase-4 in various types of ER stress-mediated 
apoptosis was reported. That includes mutant alpha-antitrypsin accumulation in the 
ER and the resultant apoptosis (Hidvegi et al., 2005); in apoptosis induced by 
Bortezomib, a ER stress inducer which increases the accumulation of misfolded 
proteins (Nawrocki et al., 2005); in plasma cell apoptosis mediated by ER stress 
(Pelletier et al., 2006); in ER stress induced by INCL (infantile neuronal ceroid 
lipofuscinosis), a neurodegenerative disorder (Kim et al., 2006); in proteosome 
inhibitor NPI-0052-induced apoptosis (used to treat chronic lymphocytic leukemia, 
CLL) (Ruiz et al., 2006); in Cephalostatin-induced ER stress-mediated apoptosis 
(Lopez-Anton et al., 2006); and in celecoxib analogue-induced tumor cell death 
mediated by ER stress (Pyrko et al., 2007)  
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1.2.4 Possible functional murine othologue 
Based on phylogenetic classification, caspase-4 belongs to the caspase-1 
group along with human and mouse caspases 1, 5, 11 and 12 (Lamkanfi et al., 2002). 
However, mouse caspases 11 and 12 do not have a corresponding functional human 
homologue. Comparing the cluster of genes at the murine chromosome locus 9A1 
with the human chromosome 11q22 locus suggests that the caspase-1 group exists 
together in a functional cluster. In humans, the inflammatory caspases, so far found 
only in vertebrates, are clustered in the following order from the telomere -- caspase-
1, caspase-5, caspase-4 and finally the gene (pseudo?) for caspase-12. The 
organization in mice is similar on chromosome 9A1, except that caspase-5 and 
caspase-4 are apparently replaced by caspase-11 (Figure 1.4). The caspase-1 
inhibitors ICEBERG and COP are found in the same locus in humans but are absent 
in mice (Martinon and Tschopp, 2004), suggesting more complicated regulation in 
humans. Caspase-4 has the highest homology with murine caspase-12 as well as -
caspase-11. Sequence comparison of the caspase domain and prodomains of the 
inflammatory caspases suggests that both caspase-4 and caspase-5 probably arose 

























Figure 1.4 Chromosomal organization and phylogenetic relationship of the 
inflammatory group of caspases. Human chromosome 11 and the corresponding mouse 
chromosome 9 encode these caspases. The black lines represent the phylogenetic relationship 
among these caspases.  
1.2.4.1 Caspase-12 
In the mouse, caspase-12 has been implicated in various types of ER stress-














Human chromosome 11 Mouse chromosome 9 
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Alzheimer’s linked presenilin-1-induced apoptosis (Siman et al., 2001; Chan et al., 
2002; Hetz et al., 2003); tunicamycin-induced apoptosis (Fujita et al., 2002); 
thapsigargin, BFA, etc. (Rao et al., 2002); and apoptosis induced  by polyglutamine 
repeats (Kouroku et al., 2002). Hence, it becomes interesting to investigate whether 
caspase-4 might have a role in ER stress-mediated apoptosis. Caspase-12 is also 
involved in hypo-responsiveness to LPS-induced production of cytokines like IL-1β, 
IL-8, etc (Saleh et al., 2004). A SNP in human caspase-12 leads to either a truncated 
protein containing the N-terminal CARD (caspase recruitment domain) or a full 
length variant that is enzymatically inactive (Saleh et al., 2004). Caspase-12 in 80% 
of the human population is truncated as a result of a single nucleotide polymorphism 
(SNP) in the fourth exon, while only 20% of individuals of African descent express 
the full length variant (Scott and Saleh, 2007) which is involved in inflammation 
(Saleh et al., 2004). The full length caspase-12 is enzymatically inactive, instead 
acting as a decoy caspase that counters LPS-induced up-regulation of various 
cytokines. More interestingly, it was shown by population genetics analysis (Xue et 
al., 2006) that the truncated form of caspase-12 arose in Africa approximately 
100,000 years ago in response to a positive selection pressure to combat rising 
infectious diseases and sepsis in Europe and Asia during migration. The relevance of 
caspase-12 signaling in ER stress induced apoptosis has been somewhat clouded by 
the fact that a human ortholog remains elusive as it has been reported that the human 
caspase-12 gene has acquired deleterious mutations that prevent the expression of a 
functional protein (Breckenridge et al., 2003; Fischer et al., 2002). 
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To understand the role of caspases-12 and -4 in apoptosis, I am including the 
following paragraphs, which analyze the paper that denied a role for these caspases in 
ER stress mediated apoptosis. 
Not all proteins are expressed in all tissues. Apart from being location 
specific, protein expression is also regulated temporally according to the 
developmental stage. The key paper that disputed the involvement of caspase-12 and 
caspase-4 in ER stress mediated apoptosis, was published in 2005 (Obeng and Boise, 
2005).  
¾ This work was done exclusively with multiple myeloma cell lines that lacked 
the expression of these caspases (Figure 1 in the paper). Even though most of the cell 
lines used for in vitro studies are transformed cell cultures, they compare like with 
like. For example, the wild-type (WT) cells expressing the protein of interest are 
compared with the same cell line, with the protein expression  knocked-out. But in 
this case, the cell line lacking caspase-4 is compared with another myeloma cell line 
expressing caspase-4. This is not a proper control as the transformed cultures already 
have innumerous variability from the physiological cells and this variation is very 
different in each myeloma line, even though they were derived from the same type of 
tissue. In the case of caspase-12 lacking lines, they used over-expression of dominant-
negative (DN) form of caspase-12 as the control (Figure 1 in the paper). This again 
does not make a proper control, as only the active caspase-12 in such a case would be 
able to restore any role that has been lost. Another significant point to note is that 
they have used DN-caspase-12 in this line to show that DN casp-12 does not protect 
the cells from ER stress mediated  
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¾ The figure 4 in the paper (Obeng and Boise, 2005) attempts to prove that caspase-
12 and caspase-4 is dispensable for ER stress mediated apoptosis. Here again 
using DN caspase-12 does not prove the point. Similarly, apoptosis. As the cell 
line is not expressing caspase-12 in the first place, how is it possible to see any 
effect with the DN caspase-12?  
¾ Another glaring shortcoming is the lack of re-expression of caspase-4 in the cell 
line lacking caspase-4.  
¾ The figures 2 and 3 in the paper (Obeng and Boise, 2005) shows that UPR was 
induced upon ER stress even in cell lines lacking caspase-12 and caspase-4. UPR 
is the primary response of the cell upon ER stress to activate the repair machinery. 
Only if UPR fails to restore normalcy, the cells move on to apoptosis. As caspases 
are downstream of this pathway, the up-regulation of UPR markers is expected 
even in cell lines lacking these caspases.use of a completely different cell line 
expressing caspase-4 does not make a proper control. 
¾ Figure 5 in the paper uses caspase inhibitors to prove the point. As the substrates 
of caspase-4 and caspase-12 are yet unidentified, there is the possibility that these 
inhibitors may not be effective in inhibiting these caspases. In addition, using it 
along with DN caspase-12 or with the cell line lacking caspase-4 does not prove 
any point as there will not be a difference anyway. 
¾ Figure 6 in the paper shows the results from the crucial experiment of putting 
back, WT-caspase-12 back into cell lines lacking caspase-12 expression and 
measuring cell death. With BFA treatment, at 1.5-2 µM, WT-caspase-12 
expressing cells are more susceptible to cell death by 25-35 %. Titrating the dose 
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and time point might yield the truer picture. However, it is obvious that caspase-
12 WT expression makes this line more susceptible to BFA induced cell death. 
Even though the difference is not clear with Tunicamycin and thapsigargin, 
titration of the dose and time response of these drugs are needed before drawing 
any conclusion. 
¾ The question arises as to why they elected not to show the data that wt caspase-12 
expressing line is more sensitive to ER stress compared to the line that lacks 
caspase-12. They contend that this is because the cell lines are different and 
cannot be compared. This argument works against all their other experimental 
results. 
¾ Figure 7 shows the caspase-4/12 activity by using a fluorogenic caspase substrate 
LEVD-AFC in all their cell lines and argue that this activity is detected even in 
cell lines lacking caspase-4 and -12. There is no known substrate of caspase-4 and 
LEVD is not specific. They use the same substrate for caspase-12 lines, as 
‘caspase-12 has 48% homology to caspase-4’. There is not even a predicted site 
for caspase-12 and using this argument is not adequate as caspases with even 
closer homology has been shown to have completely different substrate 
preferences. For e.g. Caspase-6 although structurally similar to caspase-3 and -7, 
it has a different substrate specificity with optimal substrate being VEHD rather 
than DEVD, that is preferred by caspase-3 and -7. 
¾ Another paper that denies a role for caspase-12 in ER stress mediated apoptosis 
(Saleh et al., 2006) measures cell death in only one type of cells and one time 
point and dose (supplementary figure 2 in the paper). This report emphasized the 
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inflammatory role of caspase-12 in macrophages. As caspase-12 is not the only 
major apoptotic inducer during ER stress, lack of caspase-12, could not be 
expected to afford full protection against ER stress induced apoptosis. It is indeed 
clear from many reports that ER stress mediated apoptosis feeds into the 
mitochondrial apoptotic machinery during the later stages. Bim, Bax and Bak 
knock-out mice are completely protected from ER stress mediated apoptosis 
(Puthalakath et al., 2007; Mathai et al., 2005; Hetz et al., 2006; Buytaert et al., 
2006; Ruiz-Vela et al., 2005). All these reports in no way rule out the 
participation of caspase-12 in ER stress signaling pathway. Not accepting this is 
akin to claiming that Bax and Bak do not have a role as Bim knock-out mice are 
completely protected against ER stress mediated apoptosis. All these proteins 
participate in various stages of the signaling as part of UPR and either play a 
major and indispensable role or some minor part in the execution of the final 
outcome. 
1.2.4.2 Caspase-11  
Mouse caspase-11 is a poorly characterized member of the caspase-1 family, 
in spite of the availability of knockout mice for this gene. The knockout mice show a 
similar phenotype as caspase-1 in that they fail to produce mature IL-1β and are 
resistant to endotoxic shock induced by bacterial endotoxins (Wang et al., 1998). But 
caspase-11 knock-out mice are resistant to apoptosis induced by ectopic expression of 
caspase-1, suggesting that caspase-11 is upstream of caspase-1 and unlike caspase-1, 
caspase-11 is LPS-inducible.  
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1.2.4.3 Caspase-1 and Caspase-5 
Caspase-1 is the prototype for the group of inflammatory caspases and is 
required for IL-1β and IL-18 processing as revealed by the caspase-1 knock-out mice 
data (Ghayur et al., 1997; Li et al., 1995). These mice are resistant to the lethal effects 
of LPS endotoxin. Biochemical identification and characterization of the NALP 
inflammasome (Martinon et al., 2002), a molecular platform responsible for IL-1β 
processing, has led to a better understanding of the mechanism of IL-1β regulation 
involving caspase-1 and other regulators. 
Caspase-5 along with caspase-4 does not have an exact mouse homologue. 
Based on expression profiles, caspase-5 was proposed to be the human homologue of 
caspase-11 (Lin et al., 2000). Caspase-5 together with caspase-1 was found to be a 
component of the NALP inflammasome, a complex involved in the activation of 
caspase-1 (Martinon et al., 2002). This reinforces the hypothesis that different 
inflammatory caspases may co-operate for full activity. 
 Therefore, it must be asked whether caspase-4 plays any role(s) in the innate 
immune or inflammatory responses.  
 
1.3 Apoptosis  
Apoptosis is an active, programmed process of autonomous cell death that 
avoids inflammation and is characterized by distinct morphological features (Fink and 
Cookson, 2005). Apoptotic cells are degraded into membrane-bound fragments called 
apoptotic bodies, which are rapidly engulfed by the neighboring cells or macrophages 
(Kerr et al., 1972). Regardless of the initiating death signal, all apoptotic cells exhibit 
characteristic cytoplasmic shrinkage, plasma membrane blebbing, externalization of 
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phosphatidylserine (PS), reduction of mitochondrial transmembrane potential, 
degradation of chromosomal DNA and selective cleavage of a subset of intracellular 
proteins. Caspases play a central executioner role in this process of apoptosis.  
1.3.1 Types of apoptosis 
Various stimuli activate apoptosis through one of the three major pathways: 
(i) the mitochondrial/ apoptosome pathway denoted 'intrinsic signaling', (ii) the death 
receptor pathway, denoted 'extrinsic signaling', and (iii) the CTL/NK-derived 
granzyme B-dependent pathway (Creagh et al., 2003). The basic mechanisms of 
signaling of these pathways are understood in outline, and are briefly mentioned in 
the following paragraphs. In summary, apoptosis can also be broadly classified 
according to the major organelles involved in this signaling viz., the mitochondria for 
the intrinsic pathway or cell-surface receptors for the extrinsic pathway. Nevertheless, 
there are several less well-defined caspase-activation pathways, which have recently 
being elucidated. One such pathway involves endoplasmic reticulum stress-mediated 
apoptosis activation. The endoplasmic reticulum was a much ignored entity with 
regard to its relevance in apoptosis induction till recently. I will give a detailed 
introduction about the endoplasmic reticulum and the stress pathways activated to 
gain a better understanding of this signaling, as caspase-4 has been shown to have a 
role in ER stress-mediated apoptosis (section 1.2.3). 
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Figure 1.5 Caspase-activation pathways of apoptosis: Three major pathways of 
activation with the cross-talk shown. (FADD, Fas associated death domain protein; CTL, 
cytotoxic T lymphocyte; NK, natural killer cell; Apaf-1, apoptosis protease activating factor-
1 (Creagh et al., 2003) Permission to reproduce the figure obtained from Wiley-Blackwell. 
 
1.3.1.1 Intrinsic mitochondrial stress-mediated apoptosis 
Various cytotoxic drugs, heat shock, ionizing radiation and other cellular 
stresses involve permeabilization of the mitochondrial outer membrane (Creagh et al., 
2003). These stimuli lead to release of mitochondrial components, like cytochrome c, 
to prime a caspase-9-activating complex in the cytosol (Li et al., 2000). Following 
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release from mitochondria, cytochrome c, together with apoptosis protease-activating 
factor-1 (Apaf-1), deoxyadenosine triphosphate (dATP), and procaspase-9, assembles 
into a heptameric wheel-like caspase-activating complex, termed the apoptosome 
(Acehan et al., 2002). 
Proapoptotic and antiapoptotic members of the Bcl-2 family control the 
permeability of the outer mitochondrial membrane and regulate the release of 
cytochrome c and other mitochondrial intermembrane space constituents.  
Upon activation within the apoptosome, caspase-9 propagates the death signal 
by activating downstream caspases, resulting in a caspase cascade involving caspases 
2, 3, 6, 7 and 8 (Figure 1.5).  
1.3.1.2 Extrinsic death receptor pathways of apoptosis 
Death domain-containing members of the tumor necrosis factor (TNF) 
receptor superfamily, upon engagement of their receptors by extracellular ligands like 
TNF, Fas ligand (FasL /CD95L), and TNF-related apoptosis-inducing ligand 
(TRAIL), oligomerize and undergo a conformational change in their receptor. Within 
seconds, an intracellular death-inducing signaling complex (DISC) is formed through 
recruitment of adapter molecules such as FADD (Fas associated death domain 
protein), that also contains death domain motifs (Ashkenazi and Dixit, 1998). FADD 
also contains a DED (death effector domain) and recruits the DED-containing 
protease, caspase-8, into the DISC through homotypic interactions between the DED 
motifs in both proteins (Figure 1.5).  
Caspase-8 and its related (human) caspase-10 participate in death receptor 
pathways. Upon activation of caspase-8 within the DISC, apoptosis is propagated by 
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two different mechanisms, depending on the cell type. In type I cells, stimulation 
leads to robust caspase-8 activation and other effector caspases. In type II cells, a low 
level of caspase-8 activation results in proteolysis of Bid, a Bcl-2 family member. 
Truncated Bid (tBid) translocates to mitochondria to activate the intrinsic pathway. 
Thus, cross-talk between the two pathways might occur (Creagh et al., 2003). 
1.3.1.3 Granzyme B-mediated apoptosis 
CTLs (Cytotoxic T lymphocytes) and NK (Natural killer) cells induce 
apoptosis in virally-infected and tumor cell targets by releasing cytolytic granules that 
contain a variety of enzymes that can provoke apoptosis in their target cells (Froelich 
et al., 1998). These granules contain perforin, and granzymeB a serine protease that 
cleaves caspases 3 and 8 (Figure 1.5). Granzyme B also processes several other 
caspases in vitro, suggesting multiple activation of various caspases.  
 
1.3.2 Endoplasmic reticulum and apoptosis  
1.3.2.1 Endoplasmic reticulum 
The endoplasmic reticulum is a membranous labyrinth in the cytoplasm 
extending from the nuclear envelope to the plasma membrane. The ER is a 
subcellular organelle, whose luminal volume constitutes at least one-tenth the volume 
of the cell and where the vast majority of secreted, glycosylated, and lipid proteins are 
folded into their tertiary and quarternary structure (Szegezdi et al., 2003). The ER 
serves as a unique oxidative folding environment for secretory and transmembrane 
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proteins; calcium storage and calcium signaling; and biosynthesis of steroids, 
cholesterol and lipids occur in this organelle (Schroder and Kaufman, 2005). 
Therefore, tight regulation and maintenance of ER homeostasis is vital. The ER relies 
on numerous resident chaperones, high levels of calcium and an oxidative 
environment to carry out its physiological roles in regulating protein synthesis, 
folding and targeting and maintenance of calcium homeostasis (Rao et al., 2004a).  
1.3.2.2 Endoplasmic reticulum and stress 
 
The Endoplasmic reticulum (ER) is highly sensitive to alterations in calcium 
homeostasis and other perturbations in its environment like hypoxia, misfolded 
proteins etc. Various cellular stress conditions like Ca2+ ionophores that deplete (e.g. 
thapsigargin) or increase (e.g. A23187) calcium levels from the ER lumen, inhibitors 
of glycosylation (e.g. Tunicamycin), chemical toxicants, oxidative stress and/ or 
accumulation of misfolded proteins (e.g. amyloid beta fibrils and various poly 
glutamine repeat disease models) and protein transport blockers (e.g. Brefeldin A) 
can all disrupt ER function and result in ER stress. 
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Figure 1.6 ER stress and unfolded protein response (UPR). Adaptive phase of UPR 
where the coordinated action of three systems is required for the elimination of protein 
aggregates accumulating in ER stress viz., 1. The chaperone system involving Bip/GRP78; 2. 
The PERK/PEK system that attenuates protein synthesis; 3. The ERAD system mediating 
ubiquitination and elimination of denatured proteins from the ER (Szegezdi et al., 2003) 
Permission to reproduce the figure obtained from Wiley-Blackwell. 
 
1.3.2.3 The Unfolded Protein Response (UPR) of the endoplasmic 
reticulum 
Stressors of the ER trigger a highly specific and evolutionarily conserved 
signaling pathway called the UPR or unfolded protein response that alters the 
transcriptional and translational programs to enable the cell to survive the ER stress 
(Rao et al., 2004a). This adaptive response (UPR) induces production of or activates 
ER-localized chaperones, slows down protein synthesis, induces cell cycle arrest and 
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initiates a protein degrading system (figure 1.6)  to contain and rectify the damage 
(Szegezdi et al., 2003). Unfolded proteins in the ER lumen bind to Bip/ Grp78 and 
competitively disrupt the interaction between Bip/ Grp78 and Ire-α (inositol-requiring 
kinase-1). The free Ire-α cleaves 28S rRNA and inhibits translation in the cell. ER 
stress also results in the cleavage of ATF-6 (activating transcription factor-6). Its 
cytosolic domain translocates to the nucleus, where it functions as a basic leucine 
zipper transcription factor of the ATF/CREB family, leading to the activation of 
genes possessing an ER stress element (ERSE) in the promoter region (Gotoh et al., 
2002). Such genes include chaperones such as Bip/ Grp78 and calreticulin, other 
mitochondrial stress proteins like mtDnaJ and ClpP (caseinolytic protease P) and 
transcription factors such as CHOP (Ferri and Kroemer, 2001). These newly-activated 
proteins attempt to manage the potentially harmful aberrant proteins by sequestering 
them and activating their degradation via the ubiquitin pathway. 
 
1.3.2.4 UPR and apoptosis 
 
If the stress response is unable to surmount the overwhelming damage, the 
apoptotic pathway is triggered with characteristic apoptotic morphological changes. 
This switch from metabolic arrest (which provides an opportunity for repair of the ER 
folding capacity) to cell death, which eliminates an overly damaged cell, is analogous 
to the p53 response to genotoxic stress. In contrast to the p53 switching mechanisms, 
however, the analogous processes relating to the ER remain poorly understood 
(Breckenridge et al., 2003). 
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Pharmacological agents like tunicamycin, BFA, thapsigargin and A23187 
induce ER stress and eventually trigger apoptosis within 20-48 hours, depending on 
the cell type, if ER homeostasis is not restored within a certain window of time (Patil 
and Walter, 2001). However, the exact signaling mechanism responsible for ER 
stress-mediated apoptosis remains unclear. It is known that two main pathways, a 
transcription factor and a caspase-dependent one, are activated upon ER stress 
(Szegezdi et al., 2003). In the transcription-dependent pathway, Ire1 up-regulates the 
transcription factor, GADD153/CHOP, which amplifies proapoptotic signals by 
altering the balance between Bcl-2 and Bax (Ghribi et al., 2001b; Ghribi et al., 
2001a). Also, Ire1 might activate the JNK pathway by recruiting TRAF2 (Yoneda et 
al., 2001). The second pathway is through activation of caspases, whose signaling 
scheme is largely unknown. This link between ER stress and initiation of apoptosis 
remained a mystery until the characterization of caspase-12 (Nakagawa et al., 2000). 
Caspase-12, localized on the cytoplasmic side of the ER, is activated specifically in 
response to ER stress - and caspase-12 knock-out mice are partially resistant to ER 
stress (Nakagawa et al., 2000). The mechanism of activation of caspase-12 upon ER 
stress (Figure 1.7) has been reported to proceed from the UPR (Morishima et al., 
2002; Morishima et al., 2004) through both mitochondria-dependent and 
mitochondria-independent caspase cascades.  
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Figure 1.7 UPR and apoptosis. Post-adaptive phase of UPR: The pro-apoptotic 
CHOP/GADD153 transcription factor is induced and activated, which down-regulates Bcl-2 
and results in mitochondrial cytochrome c release. A parallel pathway involving caspase-12 
activation in mice converges with a transcription-dependent pathway, both leading to 
caspase-9 and caspase-3 activation and finally apoptosis. Disruption of calcium homeostasis 
also contributes to the activation of both pathways (Szegezdi et al., 2003). Permission to 
reproduce the figure obtained from Wiley-Blackwell. 
 
Besides the transcription- and caspase-mediated pro-apoptotic pathways, a 
change in Ca2+ homeostasis activates calpain, which through cleavage of Bid and 
procaspase-12 contributes to caspase-9 activation (Nakagawa and Yuan, 2000). Also, 
pro-caspase-12 can interact with Ire1α through the adaptor TRAF2 and release 
caspase-12 for homo-dimerization and auto-processing upon ER stress (Yoneda et al., 
2001). Also, caspase-7 cleavage of caspase-12 has also been reported (Rao et al., 
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2001). All these findings imply a complex mechanism of activation of caspase-12 
(Summarized in figure 1.7). It should be noted that the role of caspase-12 in ER stress 
is complicated by conflicting findings that caspase-12 is not necessary for ER stress-
induced apoptosis (Di Sano et al., 2006; Kalai et al., 2003). Nevertheless, there are 
many more reports implicating a role for caspase-12 in ER stress-mediated apoptosis. 
It is more likely that caspase-12 does not have an absolute all or none effect in ER 
stress-mediated apoptosis, but rather acts in combination with other caspases in death 
signaling.  
1.3.2.5 ER stress and physiological diseases 
 
Several neurodegenerative diseases including Alzheimer’s disease, 
Parkinson’s disease, Huntington’s diseases (and related polyglutamine disorders), 
amyotrophic lateral sclerosis, and prion disorders share striking common features 
despite diverse clinical symptoms and transmission modes (Rousseau et al., 2004). 
The hallmark of these disorders is the progressive neuronal loss associated with the 
deposition of aggregated proteins in aberrant conformations. These aberrant 
aggregates of protein, which can be a major reason for neuronal toxicity, are excellent 
candidates for inducing ER stress, because mis-folded or malformed proteins in cells 
can trigger UPR pathway activation. It has been shown that caspase-4 is involved in 
amyloid beta-induced cell death in Alzheimer’s disease (Hitomi et al., 2004) and in 
infantile neuronal ceroid lipofuscinosis (INCL), a neurodegenerative disorder (Kim et 
al., 2006). It has become apparent that an expansion of a polyglutamine tract encoded 
by CAG repeats is the mutational mechanism underlying several neurodegenerative 
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diseases. Currently, this group consists of eight diseases viz., Huntington’s disease, x-
linked spinocerebellar muscular atrophy, dentatorubralapallidoluysian atrophy and 
five different spinocerebellar ataxias (SCA-1,2,3,6,7) (Orr, 2001). Aggregates or 
deposits of polyglutamine protein are a prominent pathological hallmark of most 
polyglutamine disorders. Covalent modification of proteins with ubiquitin and their 
subsequent degradation by the proteasomal apparatus is the major pathway by which 
the cells remove improperly folded proteins (Wilkinson, 2000). Polyglutamine 
aggregate proteins are associated with this ubiquitin as well as with components of 
proteosomal machinery and molecular chaperones (Cummings et al., 1998). This 
supports the possibility that proteins with an expanded polyglutamine tract exist in an 
abnormal conformation (Orr, 2001). All these lines of evidence leads to the theory 
that these abnormal polyglutamine proteins might trigger the typical Unfolded Protein 
Response in the ER leading to association of molecular chaperones in assisting their 
clearing by the ubiquitin degradation pathway. Apoptosis sets in when the UPR is 
overwhelmed and unable to contain the sustained damage. My investigation focuses 
on whether caspase-4 has any role in this apoptosis induced by polyglutamine 
aggregate-induced apoptosis. 
 
1.4 Inflammation  
Inflammation is essentially the effects of rapidly produced cytokines in 
response to the activation of the innate immune system, the first line of defense 
against pathogens (Medzhitov, 2001). Inflammation (Latin, inflammatio, to set on 
fire) is the complex biological response of vascular tissues to harmful stimuli, such as 
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pathogens, damaged cells, or irritants. It is a protective attempt by the organism to 
remove the injurious stimuli as well as initiate the healing process for the tissue. This 
evolutionarily ancient innate immune response helps control infections at an early 
stage by activating proinflammatory signaling cascades and also by playing an 
important role in triggering and shaping the adaptive immune response through up-
regulation of cytokines and costimulatory molecules (Janeway, Jr. and Medzhitov, 
2002).  
In the absence of inflammation, wounds and infections would never heal and 
progressive destruction of the tissue would compromise the survival of the organism. 
However, inflammation which runs unchecked can also lead to a host of diseases, 
such as hay fever, atherosclerosis, and rheumatoid arthritis. It is for this reason that 
inflammation is normally tightly regulated by the body. 
 
1.4.1 Innate immunity 
 
Immunity in higher organisms can be broadly classified into adaptive and 
innate immunity. Adaptive immunity is mediated by clonally distributed T and B 
lymphocytes which provide immunological specificity and memory. Innate immunity 
on the other hand is the inherited resistance deployed by most living organisms 
against invading pathogens and is mediated by other cells such as macrophages and 
neutrophils and traditionally classified as non-specific. However, in recent years, our 
understanding has grown by leaps and bounds after the identification of the molecular 
components involved in this signaling. In vertebrates, there is the added level of 
complexity with the presence of the highly evolved adaptive immune response. Built 
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atop the innate immune system during evolution, the adaptive immune system is 
entirely dependent upon innate immune cells and their products. At the centre of the 
innate immune response is the activation of cytokine mediators that alert other cells 
of the vertebrate host to the presence of infection. The existence of the innate immune 
system has been known for more than a century when it was first described by Elie 
Metchnikoff (Medzhitov, 2001). The fascination with the intricate and complex 
adaptive immune system overshadowed the development and understanding of this 
field.  
The signaling framework of the innate immune system emerged owing to the 
identification of Toll like receptors (TLRs) and Janeway’s hypothesis (Janeway, Jr., 
1989), which created more awareness about its complexity coupled with hitherto 
unknown specificity and indispensability to the adaptive response. Two key events 
marked the rapid progress of this field, viz. 1, The finding that the TLR4 pathway 
activation leads to the expression of costimulatory molecules for T cell activation in 
response to antigen (Medzhitov et al., 1997); and 2, Discovering that cell signaling 
induced by the powerful immunostimulatory endotoxin, LPS required TLR4 
(Poltorak et al., 1998). This led to a rapid expansion of the field, resulting in the 
identification of 10 TLRs in humans (Gay and Gangloff, 2007). 
1.4.2 Toll like receptors (TLRs) 
 
The innate immune system provides a rapid response to pathogens and, in 
contrast to the adaptive immune system, is immediately activated; it does not require 
‘priming’ or the existence of cell with ‘memory’ of earlier encounters with pathogens. 
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Such immediate activation of innate immunity relies on the detection by the host, of 
conserved microbial motifs known as pathogen-associated molecular patterns 
(PAMPs), a diverse family of molecules including lipopolysaccharide, peptidoglycan, 
bacterial lipoproteins, flagellin and nucleic acid structures from bacteria and viruses. 
After sensing the presence of a PAMP, host innate immune cells initiates a broad 
spectrum of defense mechanisms that result in the development of inflammation and 
host resistance to infection: the recruitment of professional phagocytes; the release of 
antimicrobial peptides; and the establishment of a network of cytokines, chemokines, 
and prostanoids (Akira et al., 2006). In the past decade, the research in the field of 
innate immunity advanced with the discovery of many microbial sensors called 
pattern recognition molecules. The central family of PRMs receiving considerable 
interest is the Toll-like receptor (TLR) family.  
TLRs, found on macrophages, dendritic cells and endothelial cells, are the 
pattern recognition receptors that respond to specific molecules derived from various 
pathogens. Pattern recognition receptors expressed on the surfaces of cells serve as 
sentinels waiting to alert the host to the first signs of microbial infection and to 
activate the initial line of immune defense. This sensing leads through signal 
transduction to the activation of intra-cytoplasmic mediators and transcriptional 
induction, culminating with an array of host immune responses. Cytokines and the 
complement system are the results of this signaling. 
TLRs are a family of membrane anchored proteins that have an extracellular 
signal peptide followed by multiple leucine-rich repeats, a cysteine-rich domain, a 
transmembrane domain and a cytoplasmic domain homologous to that of the 
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interleukin (IL-1) receptor. Humans express ten TLRs, enumerated 1 through 10. 
Mice do not express TLR10, but do express TLRs 1 through 9, and have two 
additional receptors (11 and 12) that are not present in humans. Each TLR is thought 
to confer the ability to recognize a discrete set of ligands. Except for TLR8 and 
TLR10, at least one ligand has been identified for each TLR. The signaling cascade 
downstream of TLR is generated from its Toll/interleukin-1 receptor (TIR) domain. 
Pathogen associated molecular patterns (PAMPs) are the highly conserved 
and unique signatures of the invading pathogen recognized by each TLR (Figure 1.8). 
PAMPs are always indispensable for the physiology and survival of that pathogen. In 
spite of the limited number of TLRs, they are able to deal with the vast majority of 
the pathogens known to man. This contradictory generality as well as the specific 
response to a particular organism is achieved via relatively few different mechanisms. 
First, different TLRs interact with a range of related environmental ligands and these 
might function in combinations to form heterodimers (Zhang et al., 2002). Second, 
other cell-surface or soluble receptors enhance and modify the ligand attachment 
thereby leading to a change in the transcriptional signal aimed at the nucleus. Third, 
the interaction of intracellular mediator molecules, the kinases and regulatory 
proteins, leads to the activation of specific set of transcription factors (Staros, 2005). 
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Figure 1.8 TLR and ligands. Different TLRs and the specific signatures that they 
recognize from different pathogens (Yamamoto et al., 2004) License number: 
1845680943867 
 
1.4.3 LPS and TLR4  
 
One such PAMP is LPS, the cell wall component of gram-negative bacteria; 
and the receptor (PRR) involved in its recognition is TLR4. Lipopolysaccharide or 
LPS (Figure 1.9) is found on the outer membrane of Gram-negative bacteria and is a 
potent activator of macrophage functions. As the name implies, LPS consists of a 
lipid region, termed lipid A, covalently linked to the polysaccharide region. The 
polysaccharide region is composed of three separate domains; an inner-core, outer 
core, and O-specific chain or O-polysaccharide. Each domain has distinct structural 
and functional properties. This type of architecture is found in a number of bacterial 
species such as Salmonella and Escherichia coli, Aeromonas and Rhizobium 
(http://www.nuigalway.ie/microbiology/mbl/lps.htm). The lipid A portion is 
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responsible for the biological activity of LPS. Stimulation of macrophages with LPS 
results in the production of various cytokines like TNFα, IL-1, IL-6, IL-8, MIP-1α/β 
and inflammatory effector substances such as protanoids, leukotrienes and nitric 
oxide (Akira, 2003a). 
The major cell surface receptor for LPS on macrophages is CD14, and LPS 
binding is greatly enhanced in the presence of LPS-binding protein (LBP). MD2 is 
another molecule that associates with TLR4 on the cell surface, which enhances the 
effect of LPS signaling (Yang et al., 2000). The formation of a LPS/LBP/CD14 
ternary complex on the cell surface activates multiple signal transduction pathways. 
LPS-binding protein and the receptor protein CD14 bind LPS, which are then 
recognized by TLR4. This interaction triggers a vigorous cell response, leading to a 
systemic release of cytokines.  
 




Sepsis, the second most common cause of morbidity in intensive care units is 
the systemic inflammatory response of the host in response to LPS endotoxin. This 
can often advance into severe sepsis involving multiple organ failure and septic shock 
leading to death (Scott and Saleh, 2007). These clinical signs and symptoms of 
septicemia can be reproduced in humans and animal models with LPS.  
1.4.4 TLR4 signaling 
 
TLR4 has a unique extracellular domain for recognizing the LPS signal, 
together with a highly homologous intracellular TIR (Toll/IL-1 Receptor) domain 
(Kopp and Medzhitov, 2003). The TIR is responsible for downstream signaling 
mainly culminating in activating the transcription factor NF-κB, which regulates the 
transcription of cytokines and other pro-inflammatory mediators, thereby acting as a 
master switch for inflammation (O'Neill, 2006). TLR4 (Figure 1.10) with its TIR 
domain interacts with the adaptor molecule MyD88/Mal, which recruits the IL-1 
receptor associated kinase-1 (IRAK1). This induces the activation of the ubiquitin 
ligase, TRAF6 that plays a central role in binding and activating various NF-κB-
activating proteins like TAK1 and IKKs (Akira et al., 2006). 
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Figure 1.10 LPS signaling via TLR4. LPS is recognized by TLR4, when it is presented 
by CD14 after binding to LBP. The internal signaling culminates in the release of pro-
inflammatory cytokines (Cohen, 2002) License number: 1845681240668 
 
TLR signaling is initiated by dimerization of TLRs, which can be either homo 
or heterodimers. All TLRs so far characterized, with the exception of TLR3, signal 
using the adaptor protein MyD88. On activation of the receptor, MyD88 is recruited 
to the receptor through its TIR domain, which interacts with the TIR domain of the 
TLR. This allows the recruitment and activation of a downstream family of kinases, 
namely IRAKs (Interleukin receptor-associated kinases) 1, 2 and 4. IRAK4 is 
recruited to the complex first, becomes activated and then phosphorylates IRAK1 
(Akira and Takeda, 2004). These kinases interact with MyD88 through the death 
domains common to both proteins, which subsequently leads to TRAF6 (Tumor 
necrosis factor receptor-associated factor 6) activation. TRAF6 occurs in a complex 
with two ubiquitin-conjugating enzymes, UEV1A and UBC13 (Akira and Takeda, 
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2004). Activation of further downstream kinases, including IKKs results in the 
release of NF-κB to translocate to the nucleus, where it mediates an increase in 
inflammatory cytokine gene expression leading to pro-inflammatory responses. A key 
component of this alert system is the transcription factor NF-κB, which mediates the 
synthesis of pro-inflammatory cytokines and their release. 
The following section looks at a few of the critical signaling components of 
the TLR4 system one by one. 
1.4.4.1 MyD88 
The TLR family signal via shared downstream signaling molecules. MyD88, 
the adaptor molecule is one of them. MyD88 was originally isolated as a myeloid 
differentiation primary response gene that is rapidly induced upon IL-6-stimulated 
differentiation of M1 myeloleukemic cells into macrophages (Lord et al., 1990). 
MyD88 consists of an N-terminal death domain (DD) separated from its C-terminal 
TIR domain by a short linker sequence. MyD88 was subsequently cloned as an 
adapter molecule that functions to recruit IRAK to the receptor complex following 
IL-1 stimulation. The association between MyD88 and IRAK is mediated through a 
DD-DD interaction. MyD88 also forms homodimers through DD-DD and TIR-TIR 
domain interactions and exists as a dimer when recruited into the receptor complex 
(Akira, 2003b). Mice deficient in MyD88 are defective in induction of serum 
cytokines in response to IL-1 and there was a block in IL-18-mediated NF-κB 





Upon LPS stimulation, IRAK-1 is recruited to the receptor through a 
homophilic interaction with the DD of MyD88. MyD88 also binds to IRAK-4 and 
thereby facilitates IRAK-4 phosphorylation of critical residues in the kinase 
activation loop of IRAK-1, thereby triggering IRAK-1’s own kinase activity (Akira, 
2003b). Once activated, IRAK-1 autophosphorylates residues in its N-terminus. 
TRAF6 is also recruited to the receptor complex via interaction with IRAK-1. Signal 
amplification by TRAF6 involves the activation of multiple kinase cascades including 
the IκB kinase (IKK), and this activation appears to involve the kinase TAK1, which 
is linked to TRAF6 via the adaptor protein TAB2. IRAK1, the signaling protein 
upstream of TRAF6 in this TLR pathway, appears to play an important role in the 
assembly of the TAK1 activation complex by bringing TAB2 from the membrane to 
TRAF6. A three-step mechanism has been proposed for this process. First, 
phosphorylated IRAK1 recruits TRAF6 to the receptor complex. IRAK1 then brings 
TRAF6 to the pre-associated complex of TAK1-TAB1-TAB2 on the membrane to 
form the huge complex with TRAF6 and IRAK1. This is then followed by 
phosphorylation of TAK1 and TAB2, disassociation of IRAK1, translocation of the 
rest of the complex to the cytosol, and the activation of IKK and NF-κB signaling. 
IRAK-1-deficient mice and cell lines showed diminished cytokine production in 






TRAF6 is a unique member of the TRAF family, which plays critical roles in 
the signal transduction of the TLR superfamily. The unique biological function of 
TRAF6 is largely a product of its distinct specificity for upstream receptors and 
signaling proteins, which is determined by its unique TRAF-C domain (Wu and 
Arron, 2003). TRAF6 can directly interact with and participate in the signal 
transduction of members of this receptor superfamily. The critical biological role of 
TRAF6 in TLR signaling has been demonstrated by the targeted deletion of TRAF6 
(Lomaga et al., 1999), where LPS-induced proliferation was dramatically reduced. 
Also, TRAF6 was shown to be required for LPS-induced NF-κB activation (Lomaga 
et al., 1999). TRAF6 recognizes a completely different binding site on its interacting 
partners compared to the other members of the TRAF family. Structural studies (Cao 
et al., 1996; Ye et al., 2002) involving TRAF6 in a complex with its binding partners 
revealed that TRAF6 recognizes a conserved Pro-X-Glu-X-X-(aromatic/acidic 
residue) motif corresponding to P-2 to P-4 residues. Of this, P-2, P0 and P3 resudues 
contribute most to the structural interaction (Figure 1.11). Further sequence 
inspection shows that other signaling proteins involved in TLR signaling like IRAK1, 
IRAK2 and IRAK-M contain one or more copies of the TRAF6-binding motif (TBS), 
providing a structural basis for the participation of TRAF6 in these pathways. TRAF6 
activates downstream NF-κB via different signaling compared to TRAF2. TRAF6 
appears to involve the assembly of a large signaling complex containing ubiquitin 
ligases, TAK1 and TABs, for which non-degradative polyubiquitination may be 
required (Deng et al., 2000; Wang et al., 2001). The RING domain of TRAF6 is 
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required for this IKK activation leading to NF-κB signaling, probably by acting as an 
E3 ubiquitin ligase. 
                            
Figure 1.11 TRAF6 binding site 
Surface representation of TRAF6 and the bound interacting partner (eg. TRANCE) (Ye et al., 
2002) License number: 1845681414088 
1.4.4.4 NF-κB 
 
Immune responses can be broken down into individual signal transduction 
events through which changes in the extra-cellular environment elicit altered gene 
expression at the cellular level. In a remarkable number of instances, NF-κB is the 
transcription factor that mediates these transcriptional changes. The transcription 
factor NF-κB has attracted widespread attention among researchers in many fields 
based on the following: its unusual and rapid regulation, the wide range of genes that 
it controls, its central role in immunological processes, the complexity of its subunits, 
and its apparent involvement in several diseases. NF-κB plays a critical role in 
immune and inflammatory responses (Akira, 2003a). NF-κB is a dimer composed of 
members of the Rel family of DNA-binding proteins, RelA/p65, p50, p52, c-Rel, 
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RelB, and Bcl-3. A majority of inducers of NF-κB, including LPS are known to 
operate via a canonical pathway (Figure 1.12) that culminates in the degradation of 
IκB proteins. In most cell tpes, NF-κB is inactive and is sequestered in the cytoplasm 
because of its association with the inhibitory IκB proteins. Activation of NF-κB by 
various stimuli involves the phosphorylation of IκB proteins on highly conserved 
serine residues by a 900 kDa kinase complex called the IκB kinases (IKKs), 
triggering their degradation and the release of NF-κB, which translocates into the 
nucleus and activates various target genes (Tergaonkar, 2006). The promoters of most 
inflammatory genes have NF-κB-binding site(s). NF-κB has been observed to 
translocate to the nucleus in LPS-stimulated macrophages, and has been implicated in 
the LPS-induced gene regulation of proinflammatory cytokines and inflammatory 
mediators (Dendorfer et al., 1994; Liu et al., 1997; Ni et al., 1998; Xie et al., 1994). 
Targeting RelA/p65, IκBα and use of NF-κB inhibitors also reduced LPS-induced 
cytokine up-regulation. Also, IKKβ has been shown to be critical for NF-κB 
activation by LPS (Li et al., 1999; Tanaka et al., 1999).  
Under baseline conditions, in the healthy human, NF-κB functions in 
regulating the expression of genes involved in normal immunologic responses, such 
as generation of antibody light chains and other immunoregulatory molecules. Rapid 
mobilization of an acute inflammatory response is necessary for defense against 
external biological assaults to the organism, like bacterial invasion (LPS is the 
PAMP). However, excessive activation of NF-κB results in enhanced expression of 
pro-inflammatory cytokines like IL-1β that leads to inflammatory diseases, such as 
septic shock, psoriasis, asthma and rheumatoid arthritis (Tobe et al., 2003).  
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Figure 1.12 NF-κB canonical pathway. 
The p65/p50 subunits of the NF-κB heterodimer are sequestered in the cytoplasm in the 
inactive form by IκBα, which upon phosphorylation by IKKα/β, is degraded by 
ubiquitination, and the NF-κB subunit is free to translocate to the nucleus and function as a 
transcription factor  (Braun et al., 2006). License number: 1845690164981 
This key role played by NF-κB in controlling the expression of multiple 
inflammatory and immune genes involved in these diseases makes it important to 




The gene products characteristic of early events in immune responses include 
cytokines (including chemokines) that propagate and amplify the initial recognition 
event. Cytokines are low molecular weight proteins that play roles in signaling during 
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inflammation. Cytokines are local protein mediators, now known to be involved in 
almost all important biological processes, including cell growth and activation, 
inflammation, immunity, and differentiation. Due to their central role in the immune 
system, cytokines are involved in a variety of immunological, inflammatory and 
infectious diseases. I will very briefly highlight a few cytokines in the context of LPS 
signaling.  
1.4.4.5.1 IL-8 
The chemotactic factor IL-8, the best characterized member of the CXC 
chemokine family, is a potent activator and chemo-attractant of neutrophils, and acts 
on T cells, basophils and eosinophils. IL-8 is produced by a wide variety of cells, 
including monocytes/macrophages, after exposure to inflammatory stimuli like LPS. 
Many  diverse forms of acute and chronic inflammatory diseases are characterized by 
the local accumulation of inflammatory cells, including neutrophils and lymphocytes 
(Delgado and Ganea, 2003). IL-8 participates in the pathogenesis of various 
inflammatory diseases and its levels are often correlated with the pathology, severity 
and the disease outcome. Therefore, although IL-8 plays a beneficial and central role 
in the inflammatory response, hematopoiesis, and angiogenesis, excessive IL-8 
production can be deleterious to the host and its selective inhibition represents an 
important therapeutic goal.  
1.4.4.5.2 MIP-1β 
MIP-1β, a member of the CC chemokine subfamily, is another LPS inducible 
chemokine, especially in human monocytes. It is a potent chemoattractant for 
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monocytes, immature dendritic cells and coronary endothelial cells (Menten et al., 
2002) 
1.4.4.5.3 MIP-3α 
MIP-3α/ CCL20, alternatively named liver and activation-regulated 
chemokine (LARC) is the only chemokine interacting with the CC chemokine 
receptor 6 (CCR6), a property shared with the antimicrobial β-defensins. This is 
responsible for the chemoattraction of immature dendritic cells, effector/memory T-
cells or B cells and plays a role at skin and mucosal surfaces under homeostatic and 
inflammatory conditions, as well as in pathologies, including cancer and rheumatoid 
arthritis (Schutyser et al., 2003). LPS is known to be a potent inducer of the mRNA as 
well as the protein of MIP-3α. 
1.4.4.5.4 IL-1β 
IL-1β is a major mediator of inflammation and in general, initiates and/ or 
amplifies a wide variety of effects associated with innate immunity and host 
responses to LPS (Martinon and Tschopp, 2007). IL-1β induces fever, slow-wave 
sleep, anorexia and inflammatory pain hypersensitivity, typically associated with 
infections/ injury. It also contributes to arteriosclerosis, tumor angiogenesis and 
invasiveness of different tumor cells. 
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1.5 Thesis rationale 
Based on phylogenetic data, human caspases 4 and 5 appear to have arisen out 
of gene duplication from the caspase-1 cluster locus in the mouse. As neither is 
completely homologous to mouse caspases 11 or 12, coupled with the fact that human 
caspase-12 is a pseudogene in most of the human population, the function of these 
caspases is predicted to be carried out by one or other of the known caspases. 
Caspase-4 is an ideal candidate for investigating both the apoptotic role of caspase-12 
and the inflammatory role of caspases 11 and 12.  
Apoptotic role:  
As caspase-4 is implicated in various types of ER stress and thought to act in a 
cell type-specific fashion, I wanted to investigate whether caspase-4 has any role in 
ER stress-mediated apoptosis in the human neuroblastoma cell line SHEP1. To put 
this in the context of physiological relevance, I explored the possibility that caspase-4 
might play a role in mediating ER stress induced by expanded polyglutamine repeats 
in the neurodegenerative disorder scenario.  
Inflammatory role:  
In the absence of a murine homologue of caspase-4, I used human cell lines to 
address the role of caspase-4 in the innate immune responses to LPS. A particular 
advantage of using cells from humans compared with mice is the frequent and 
substantial species differences in their immune systems; for example, the absence of 
an exact homologue of human IL-8 in mice (Guenet, 2005; Mukaida et al., 1998). 
Using shRNA knockdown technology, I generated stable human monocytic cell lines 
with massively reduced expression of caspase-4 in order to investigate deficiencies in 
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LPS-induced cytokine up-regulation in the caspase-4-deficient cells. The subsequent 
identification of cytokines which depend on caspase-4 for their expression and 
secretion should allow me to trace the signaling pathways from TLR4 that lead to and 








2. CHAPTER 2. Materials and Methods 
2.1 Chemicals and reagents 
Bovine serum albumin (BSA), ampicillin, kanamycin, penicillin-streptomycin, 
LPS, were from Sigma Aldrich. U0216 was from Cell signaling. The Dual luciferase 
assay kit was purchased from Promega.  Acrylamide/Bisacrylamide and non-fat milk 
were from Bio-Rad. DEVD-afc and z-LEVD-fmk were obtained from BACHEM. 
Protein A/G plus-agarose was from Santa Cruz. Other chemicals or reagents are 
individually mentioned in the following sections where relevant. 
All antibodies used in the research are listed in table 2.1.   
 
Table 2.1 Antibodies used in the research 
Name Host/Clone Source;Catalogue number 
Actin Mouse/Monoclonal Sigma; A5060 
Calreticulin Rabbit/Polyclonal Sigma; C4606 
Caspase-1 Rabbit/Polyclonal Santa Cruz; SC-622 
Caspase-4 Mouse/Monoclonal MBL; M029-3 
Caspase-4 p20 Goat/Polyclonal Santa Cruz; SC-1229 
Caspase-8 Mouse/Monoclonal MBL; M058-3 
c-myc Mouse/Monoclonal Sigam; M5546 
Fas Mouse/Monoclonal Upstate; 05-201 
FLAG Mouse/Monoclonal Sigma; F3165 
GM130 Mouse/Monoclonal BD transduction 
laboratories; 610823 
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GRP78 Goat/Polyclonal Santa Cruz; SC-1050 
IKKα Mouse/Monoclonal BD Pharmingen; 556532 
IKKβ Mouse/Monoclonal BD Pharmingen; 550621 
IRAK-1 Mouse/Monoclonal Santa Cruz; SC-5288 
NF-κB p50 Rabbit/Polyclonal Santa Cruz; SC-7178 
NF-κB p65 Rabbit/Polyclonal Santa Cruz; SC-372 
Phospho-IKKα/β Rabbit/Polyclonal Cell Signaling; 2687 
Phospho-IκBα Mouse/Monoclonal Cell Signaling; 9246 
TRAF6 Mouse/Monoclonal Santa Cruz; SC-8409 
Tubulin Mouse/Monoclonal BD Pharmingen; C4585 
 
 
2.2 Cell culture  
SHEP1, 293 and 293T cells were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM, Sigma) supplemented with 4.5 g/L glucose, 10% (v/v) fetal bovine 
serum (FBS, Hyclone), 100 units/ml penicillin and 100 ng/ml streptomycin (Sigma) 
in a humidified incubator containing 5% CO2. The human moncytic cell lines, THP1 
(ATCC TIB-202) and U937 (ATCC CRL-1593.2), were maintained in RPMI medium 
supplemented with 10% heat inactivated FBS, 2mM L-glutamine, 100 U/ml of 
penicillin and 100 ug/ml of streptomycin at 37°C in a humidified incubator with 5% 
CO2. Stable cells were selected and maintained in hygromycin (BD Bioscience), 
G418 (Calbiochem) accordingly. (See Table 2.2) 
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2.3 Transfection of mammalian cells 
2.3.1 Transient transfection using LIPOFECTIN 
Approximately 1-2 × 105 cells were seeded onto 6-well or 35-mm tissue culture 
plates 16 h before transfection. 6 µl of LIPOFECTIN (Invitrogen) was diluted into 
100 µl of opti-MEM medium (Invitrogen) and incubated at room temperature for 30-
35 min. 1-2 µg of plasmid DNA was diluted into 100 µl of opti-MEM medium and 
combined together with the LIPOFECTIN-opti-MEM mixture. The DNA-
LIPOFECTIN mixture was incubated at room temperature for 15 min and topped up 
with opti-MEM to 1 ml. Cells were rinsed with opti-MEM medium followed by 
incubation with the transfection mixture for 8-10 h at 37ºC. Subsequently, the 
transfection mixture was removed and the cells were incubated for another 40 h in 
complete growth medium before treatment. 
2.3.2 Transient transfection using FUGENE6 
 
Cells were seeded in antibiotic free medium one day before transfection in 6 
well plates. 3.5 µl Fugene6 was added to an eppendorf containing 95 µl serum free 
medium. After 5 minutes incubation, 1 µg DNA was added and the mix incubated for 
atleast 20 minutes for complex formation. This complex was added to the cells 
dropwise into the culture in wells. The transfection was allowed to proceed for at 




2.3.2 Stable transfection by electroporation 
 
Approximately 106 cells were centrifuged and washed with PBS once, and the 
pellet was resuspended in 500µl serum free medium. 2µg of linearized plasmid was 
added to the suspension on ice, mixed and incubated for 10 minutes on ice. Using the 
‘Gene Pulsar’ from Biorad with a capacitance set at 960 µFD and 280 volts, 
electroporation was achieved with a time constant of 25-30. The cells were put back 
on ice and after a recovery period of 5 minutes diluted in 40 ml of complete medium. 
This was split in 96 well plates at the rate of ~1000 cells per well. After incubation 
for 24 hours, the cells were subjected to 500µg/ml selection medium for two weeks 
until the colonies were visible. The colonies were picked up for testing and further 
propagation. After confirming the expression of the stable gene, they were maintained 
in 50 µg/ml of selection antibiotic in complete medium. 
 
Table 2.2 Stable cell lines used in the current study 
Cell lines Medium Description Source 
SA DMEM/H SHEP1 cells stably expressing 
shRNA against caspase-4 
Own construction 
SB DMEM/H SHEP1 cells stably expressing 
shRNA against caspase-4 
Own construction 
SC DMEM/H SHEP1 cells stably expressing 
shRNA against caspase-4 
Own construction 
SD DMEM/H SHEP1 cells stably expressing 
shRNA against caspase-4 
Own construction 
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SVC DMEM/H SHEP1 cells stably expressing 
shRNA against non specific 
nonsense sequence 
Own construction 
TA RPMI/H THP1 cells stably expressing 
shRNA against caspase-4 
Own construction 
TB RPMI/H THP1 cells stably expressing 
shRNA against caspase-4 
Own construction 
TC RPMI/H THP1 cells stably expressing 
shRNA against caspase-4 
Own construction 
TD RPMI/H THP1 cells stably expressing 
shRNA against caspase-4 
Own construction 
TVC RPMI/H THP1 cells stably expressing 
shRNA against non specific 
nonsense sequence 
Own construction 
H: Hygromycin at 50 µg/ml 
 
2.4 Molecular cloning 
2.4.1 Construction of expression plasmids 
 
Caspase-4 fused to GFP was cloned into the pEGFP N2 vector from Clontech 
between the EcoR1 and kpn1 site of the MCS, such that GFP was on the carboxyl 
terminus of caspase-4. pEGFP-72CAG and pEGFP-11CAG plasmids encoding the 
expanded CAG (polyglutamine) repeats cloned into the EcoRI site were a generous 
gift of Dr. Takashi Momoi (National Institute of Neuroscience, Tokyo, Japan). The 
NF-κB luciferase reporter plasmid and the renilla luciferase reporter were provided 
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by Dr. Li Lei and Dr. S. Dhakshinamoorthy from our laboratory, respectively. 
Mutants A, B and C (TRAF6-binding site in caspase-4) were created one by one 
using the QuikChange® II XL site-directed mutagenesis kit from Stratagene in the 
pEGFP plasmid from Clontech. The sequences of mutants A, B and C were, 
respectively, PPASGE (CCA CCT GCG TCA GGA GAA); APASGE (GCA CCT 
GCG TCA GGA GAA) and APASGA (GCA CCT GCG TCA GGA GCA). Caspase-
4 tagged with c-myc at the carboxyl terminus and TRAF6 tagged with FLAG at the N 
terminus was cloned into the pEGFP plasmid from Clontech after removal of the 
eGFP tag. An active site mutant of caspase-4 was generated by the quik change kit 
from Stratagene. Caspase-1-c-myc was also cloned into pEGFP from Clontech 
between Eco RI and Kpn I after removing eGFP. The pEGFP N2 empty plasmid after 
removal of eGFP served as the negative control in all experiments. 
2.4.2 Preparation of Escherichia coli competent cells 
 
The DH5α, XL-blue E. coli strain was streaked onto an LB (pH 7.5) agar 
plate (containing 1% bacto-tryptone, 0.5% bacto-yeast extract, 1% NaCl, and 1.5% 
agar) without antibiotics and incubated at 37°C overnight.  A single colony was 
inoculated into 30 ml of LB and grown at 37°C with shaking.  The overnight culture 
was added to OD600 0.1 in 400 ml of LB and grown for approximately 3 h at 37°C to 
reach OD600 0.3-0.6.  The bacterial culture was harvested by centrifugation at 4000 
rpm for 10 min at 4°C.  The pellet was washed on ice in 100 ml of 100 mM CaCl2. 
Subsequently, the bacteria were centrifuged again at 4000 rpm for 10 min at 4°C. The 
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pellet was resuspended in 8 ml of 100 mM CaCl2 with 10% glycerol. The competent 
cells were aliquoted and stored at –80°C. 
2.4.3 DNA transformation 
 
The ligated DNA (5 μl, about 100 ng) or pure plasmid DNA (about 10 ng) 
was mixed with 100 μl of competent cells, which were pre-thawed on ice. After the 
mixture was incubated on ice for 30 min, the cells were heat-shocked for 90 seconds 
at 42°C followed by placing on ice for 10 min. For ampicillin-resistant plasmids, the 
cells were directly spread onto the LB agar plates containing 50 μg/ml ampicillin.  
For plasmids with kanamycin resistance genes, 1 ml of LB was added to the heat-
shocked cells followed by shaking at 37°C for 1 h. Before the cells were spread onto 
LB plates containing the appropriate antibiotic, a brief centrifugation of the cells in a 
micro-centrifuge was performed to reduce the volume.  
2.4.4 DNA preparation 
 
Small-scale plasmid DNA isolation from E. coli cultures was carried out using 
the Rapid Plasmid Miniprep System (Marligen Bioscience, MD, USA) according to 
the manufacturer’s instruction.  The overnight bacterial culture was harvested by 
centrifugation at 14,000 rpm for 5 min, and the supernatant was discarded.  The cell 
pellet was completely resuspended in Cell Resuspension Solution [50 mM Tris-HCl 
(pH 7.5), 10 mM EDTA, and 100 μg/ml RNase A], followed by the addition of Cell 
Lysis Solution (0.2 M NaOH and 1% SDS), Alkaline Protease Solution and  
Neutralization Solution (4.09 M guanidine hydrochloride, 0.759 M potassium acetate 
and 2.12 M glacial acetic acid, pH 4.2).  The bacterial lysate was centrifuged at 
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14,000 rpm for 10 min at room temperature, and the cleared lysate was transferred to 
a Spin Column. After centrifugation for 1 min, the Wash Solution, diluted with 95% 
ethanol, was added to the Spin Column (162.8 mM potassium acetate and 27.1 mM 
Tris-HCl, pH 7.5), followed by another centrifugation.The wash procedure was 
repeated again before the plasmid DNA was eluted in an appropriate amount of TE or 
nuclease-free water.  
Large-scale plasmid DNA isolation was carried out by using the QIAGEN 
Plasmid Maxi Kit (QIAGEN) according to the manufacturer’s instructions. Similar to 
the miniprep process, large volumes of bacterial culture were centrifuged into pellets 
and subsequently incubated with the resuspension, lysis and neutralization buffers 
sequentially. After clearing of the bacterial lysate by centrifugation, the supernatant 
was applied to a the pre-equilibrated QIAGEN-tip 500 column, followed by washing 
with wash buffer (1 M NaCl, 50 mM MOPS pH 7.0 and 15% isopropanol).  The 
plasmid DNA was eluted by elution buffer (1.25 M NaCl, 50 mM TrisCl pH 7.0 and 
15% isopropanol) and precipitated by 0.7 volumes of isopropanol.  The DNA pellet 
was washed with 70% ethanol, air-dried, and redissolved in a suitable volume of TE 
buffer or nuclease-free water. 
Genomic DNA isolation was carried out using the QIAGEN DNA mini kit. 
Cells from one 80 cm2 flask (NUNC, Denmark) were harvested, washed once with 
ice-cold PBS and centrifuged at 2000 rpm for 5 min at 4ºC. The cells were 
resuspended in 1 ml of PBS. 1 ml of ice-cold lysis buffer (1.28 M sucrose; 40 mM 
Tris·Cl, pH 7.5; 20 mM MgCl2; 4% Triton X-100) and 3 ml of H2O were added into 
the cell suspensions. The mixture was incubated on ice for 10 min and subjected to 
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centrifugation at 2000 rpm for 15 min at 4ºC. The supernatant was discarded and the 
pellets were resuspended in 0.5 ml of lysis buffer and 1.5 ml of H2O. The mixture 
was vortexed and centrifuged at 2000 rpm for 15 min at 4ºC. The supernatant was 
discarded and 1 ml of digestion buffer (800 mM guanidine HCl; 30 mM Tris-Cl, pH 
8.0; 30 mM EDTA, pH 8.0; 5% Tween-20; 0.5% Tritin X-100) was added to 
resuspend the pelleted nuclei. The nuclei were vortexed at maximum speed for 30 
sec. 50 µl of protease was added into the nuclei followed by the incubation at 50ºC 
for 30 min. The sample was vortexed after lysis for 10 sec at maximum speed and 
applied to the pre-equilibrated QIAGEN genomic tip. The tip was washed with 3 × 1 
ml of wash buffer (1.0 mM NaCl; 50 mM MOPS, pH 7.0; 15% isopropanol) and the 
genomic DNA eluted with prewarmed elution buffer (1.25 mM NaCl; 50 mM Tris.Cl, 
pH 8.5; 15% isopropanol). The DNA was precipitated by adding 0.7 volume of 
isopropanol to the eluted DNA and spun down. The DNA was air-dried and dissolved 
in TE or nuclease free H2O.  
 
2.5 Polymerase chain reaction (PCR) 
PCR for cloning purposes was performed by using the expand Hifi DNA 
polymerase (Roche) and the primers of the required sequences were synthesized by 
Genset Inc., Singapore.  Typically, to amplify DNA fragments, 20-50 ng of cDNA 
template in the PCR buffer was supplemented with 1.75 mM MgCl2, and mixed with 
250 μM of the deoxy-adenine, deoxy-cytosine, deoxy-guanine and deoxy-thymidine 
nucleotides (QIAGEN), 50 pM of the sense and anti-sense primers, and 2.5 Units of 
the Hifi DNA polymerase (Roche).  The reaction was carried out by 1 cycle of 
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denaturation at 94°C for 2 min and primer annealing at 50-60°C for 30 sec 
(dependent on the primers used), followed by 30 cycles of DNA extension at 68°C for 
up to 2 min (dependent on the length of the PCR product), denaturation at 93°C for 
15 sec, and primer annealing at 50-60°C for 30 sec.  A final cycle of DNA extension 
was carried out at 68°C for 7 min. For the PCR reaction for non-cloning purpose, Taq 
DNA polymerase (QIAGEN) was used.  
 
2.6 Site-directed mutagenesis 
Point mutations were introduced into the plasmid cDNAs using the 
QuikChangeTM Site-Directed Mutagenesis Kit (Stratagene). Complementary primers 
with point mutations were designed and used for extension in temperature cycling to 
generate mutant plasmids from the wild-type plasmid template.  The temperature-
cycling conditions involved 16 cycles of denaturation at 95°C for 30 sec, primer 
annealing at 50°C for 1 min, and extension at 68°C for 14 min (based on 2 min/kb of 
plasmid length).  The methylated wild-type template was removed from the newly 
synthesised, non-methylated plasmids by DpnI (New England Biolabs) restriction 
digest at 37°C for 1h.  The mutant plasmids were transformed in E. coli for clonal 




2.7 Sytox/Hoechst (S/H) DNA staining  
S/H staining is an easy and quick way to distinguish between necrosis (passive 
cell death) and apoptosis (active, programmed cell death). Hoechst-33342 (Molecular 
Probes) is a blue membrane permeable DNA dye, and sytox (Molecular Probes) is a 
green membrane impermeable DNA dye. When applied to cells, normal healthy 
control cells with intact cell membranes display round and blue nuclei, whereas 
apoptotic (Sytox-impermeable membrane, only H-33342-stained) show blue strongly 
condensed/fragmented nuclei. In contrast, necrotic cells (damaged and therefore 
Sytox-permeable membrane) appear swollen-greenish.  
After treatment, the Sytox/ Hoechst stain was added into the cell culture 
medium at final concentration of 500 nM and 500 ng/ml respectively and the cells 
were incubated at 37˚C for up to 5 min. Cells were then visualized under the Zeiss 
epifluorescence microscope, and photos were taken with an attached Nikon Coolpix 
digital camera.  
 
2.8 Cell death assay 
Three different methods assaying cell death based on different principles were 
used in my research. Although the absolute values might be different by using these 
different methods, the pattern of death was similar. LDH is a stable cytoplasmic 
enzyme present in all cells and is rapidly released into the cell culture medium when 
the plasma membrane is damaged. The percentage of LDH release is proportional to 
percentage of damaged cells. WST is a tetrazolium salt which can be cleaved by 
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mitochondrial enzymes in metabolically active cells to form a water-insoluble 
formazen, which can be directly measured in an ELISA plate reader. The healthier the 
cells are, the higher the WST reading will be. Trypan Blue stain exclusion is the basis 
for the third method employing the automated Vi Cell counter. 
 
LDH (lactate dehydrogenase) release assay. Cells (1-2 × 104 /well) were plated in 
96-well plates and subjected to the desired treatments. After the treatment, the 
supernatants of the cells were collected, and the cell layer was lysed with an equal 
volume of lysis buffer (DME plus 0.1% Triton X-100). LDH activity in the 
supernatant and the lysate was quantitated. The cytotoxicity was calculated as 
percentage of LDH release by the ratio of supernatant/ (lysate + supernatant). 
WST assay. Cells (1-2 × 104 /well) were plated in 96-well plates and subjected to the 
desired treatments. After treatment, WST was added into each well at 1:10 dilution. 
The cells were further incubated in a 37ºC incubator until the color changed and 
subjected to measurement at 420-480 nm. 
ViCell Counting: Cells were trypsinized and resuspended in their supernatant, and 2 
ml was taken for the assay. The cell suspensions were transferred to cuvettes and 
placed in the slots on Vi Cell Counter. The ViCell counter stains the cells with trypan 
blue, and the live cells exclude the blue stain on account of their intact plasma 
membrane, while the dead cells take up the stain. The results are are quantified based 
on pictures taken from 50 different fields. 
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2.9 Reporter assay 
THP1 cells were seeded one day before transfection in serum free medium, and 
transfected in triplicates with NF-κB firefly luciferase reporter and control Renilla 
luciferase reporter plasmid in the ratio of 10:1 along with various combinations of 
plasmids used for testing with a final DNA concentration of 1µg using Fugene6. 
After 36 hours, the cells were treated with LPS (1µg/ml) for four hours and the cells 
harvested and washed in PBS once, before lysing it in 100 µl passive lysis buffer for 
30 minutes to 1 hour. 40-50 µl of the lysate was subjected to dual luciferase reporter 
assay using either the T20 luminometer or Glomax luminometer from Promega.  
 
2.10 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
The Bio-Rad Mini-PROTEAN II system was used for protein gel 
electrophoresis.  The resolving gels included 6-15% acrylamide (29:1) (Bio-Rad), 
0.375 M Tris-HCl pH 8.8 and 0.1% (w/v) SDS, and were polymerized by the addition 
of freshly prepared 0.1% (w/v) ammonium persulfate and 0.01% (v/v) TEMED.  The 
stacking gels included 4% acrylamide, 0.125 M Tris-HCl, pH 6.8, and 0.1% SDS, and 
were polymerized as described for the separating gels.  Protein samples were mixed 
with an equal volume of 2X protein sample buffer [2X: 125 mM Tris-HCl (pH 6.8), 
4% SDS (v/v), 10% β-mercaptoethanol (v/v), 20% glycerol (v/v) and 0.4% 
bromophenol blue (w/v)], and heated at 95°C for 5 min before loading into the wells.  
Electrophoresis buffer consisted of 25 mM Tris-HCl (pH 8.3), 192 mM glycine and 
0.1% SDS.  The gels were subjected to electroblotting onto polyvinylidene difluoride 
(PVDF) membrane (Millipore) for Western blot analysis. 
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2.11 Western blot analysis 
After SDS-PAGE, the resolved proteins were electroblotted onto a PVDF 
membrane (pre-activated with methanol) using the Bio-Rad Trans-BlotTM system.  
Electroblotting was carried out in the transfer buffer composed of 25 mM Tris-base, 
192 mM glycine, and 20% methanol for 1 h at 4°C.  The membrane was then 
incubated in blocking buffer [PBS containing 5% (w/v) non-fat milk (Bio-Rad) or 
BSA and 0.1% (v/v) polyoxyethylene-sorbitan monolaurate (Tween-20, Sigma)] for 
at least 1 h.  The membrane was then incubated with the relevant antibodies diluted in 
blocking buffer to the optimized working concentrations for overnight incubation at 
4ºC.  Unbound antibodies were removed by extensive washing in PBS containing 
0.1% Tween-20.  After incubation with the secondary antibody for about 2 h at room 
temperature and washing with PBS containing 0.1% Tween 20, the membrane was 
then developed using an enhanced chemiluminescence (ECL) kit. 
For reprobing of the same membrane with a different antibody, the immunoblot 
was incubated in stripping buffer [62.5 mM Tris (pH 6.8), 100 mM β-
mercaptoethanol, and 2% SDS] for 30 min at 60°C to remove the previous antibody. 
The membrane was then re-blocked with blocking buffer and incubated with another 
antibody. 
 
2.12 Phosphorylation detection 
Cells were harvested after different times of 1 µg/ml LPS treatment and lysed in 
50 µl of sample buffer (62.5 mM Tris-HCl, pH 6.8,  2% SDS, 10% glycerol, 0.1% 
bromphenol blue and 50 mM freshly added DTT). Sonication was needed to shear the 
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genomic DNA and reduce the viscosity of the lysates. The sonicated lysate was then 
heated at 99°C for 5 min and subjected to centrifugation at 14,000 rpm for 5 min at 
4°C. 50 μl of the supernatants was separated on 8% of polyacrylamide gels and 
transferred onto PVDF membranes (Millipore). Detection of bands was performed 
using the Phototope®-HRP Western Blot Detection System (Cell Signaling) and the 
washing was done in TBST. 
 
2.13 RNA preparation 
Cells grown in monolayer were lysed directly in a culture dish. The media was 
decanted, TRI REAGENT was added, and the cell lysate was passed several times 
through a pipette. For suspension cells, cells were pelleted first and then lysed in TRI 
reagent. 1 ml of TRI REAGENT (Invitrogen) was used per 10 cm2 of culture dish 
area. The homogenate was stored for 5 min at room temperature to permit the 
complete dissociation of nucleoprotein complexes. 0.2 ml chloroform was added into 
the 1 ml of homogenate and the mixture was vortexed for 15 sec. The mixture was 
stored at room temperature for 15 min and subjected to centrifugation at 12,000 g for 
15 min at 4ºC. After centrifugation, the supernatant was carefully transferred into a 
fresh tube. RNA from the supernatant was precipitated by mixing with isopropanol 
(Use 0.5 ml of isopropanol per 1 ml of TRI REAGENT used for the initial 
homogenization.). The samples were stored at room temperature for 10 min and 
centrifuged at 12,000 g for 8 min at 4ºC. The supernatant was removed, and the RNA 
pellet was washed with 75% ethanol and centrifuged at 7,500 g for 5 min at 4ºC. The 
ethanol wash was removed and the RNA pellet was air-dried for 3-5 min at room 
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temperature. RNA was finally dissolved in RNase-free H2O and frozen for further 
use. 
Total RNA (less than 250 µg) was diluted with RNase-free water to 250 µl, 
incubated with 15 µl of Oligotex resin (QIAGEN) and 250 µl of OBB. The mixture 
was thoroughly mixed by pipetting and incubated at 70ºC for 3 min followed by an 
incubation at room temperature for 10 min, allowing the hybridization between the 
oligo dT30 of the Oligotex particle and the poly-A tail of the mRNA. Oligotex:mRNA 
complexes were collected by centrifugation for 2 min at maximum 14,000 g. The 
supernatant was carefully removed by pipetting and the pellet was resuspended in 400 
µl of buffer OW2 by votexing, added onto a small spin column (supplied in the kit) 
which was placed in a 1.5 ml microcentrifuge tube and centrifuged for 1 min at 
maximum speed (14,000 rpm). The spin column was transferred to a new RNase-free 
1.5 ml microcentrifuge tube, and 400 µl of buffer OW2 was applied to the column. A 
short centrifugation was performed for 1 min at maximum speed, and the flow-
through was discarded. The spin column was transferred to a new RNase-free 1.5 ml 
microcentrifuge tube and 50 µl hot (70ºC) buffer OEB was pipetted onto the column, 
and 3-4 up and down pipetting steps were applied to resuspend the resin. A final 
centrifugation was carried out for 1 min at maximum speed to elute the mRNA. To 
concentrate the mRNA obtained, a precipitation step may be required. mRNA (at the 
starting volume of 50 µl) was mixed with 40 µl of 1×TE, 1 µl of glycogen (5 mg/ml), 
10 µl of 3M NaAc (pH 5.2) and 250 µl of 100% ethanol. The mixture was frozen at   
-80ºC for 20 min and subject to centrifugation for 20 min at 12,000 g at 4ºC; the 
supernatant was removed and 250 µl of 75% ethanol was applied to wash the pellet. 
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Centrifugation at 12,000 g for 5 min was performed, the supernatant was removed 
and the pellet was air-dried. The pellet was dissolved in an appropriate volume of 
RNase-free water and frozen for further use. 
2.14 Human cytokine array, RT-PCR and ELISA assays 
Rapid analysis of the secreted cytokines and chemokines was performed using the 
Raybio™ kit from Raybiotech Inc., USA, and spots were quantified with a Biorad 
densitometer using the software ‘Quantityone’. For RT-PCR analysis, total RNA was 
isolated by the Trizol method using the TRI reagent from Molecular Research Center, 
Inc., and cDNA was synthesized using Superscript™ first strand synthesis kit from 
Invitrogen. The SingleGene™ PCR kit from SuperArray Bioscience Corporation was 
used for gene-specific PCR expression analysis of the following cytokines or 
chemokines, viz., IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-11, IL-12A, IL-12B, 
IL-18, IFN-γ, CCL4 (MIP-1β), CCL20 (MIP-3α), CCL2 (MCP-1), CCR2, M-CSF, 
CCL5 (RANTES) and TNFα, along with GAPDH, the internal control for 
normalization. Agarose gel images were scanned and analyzed using a Biorad 
densitometer and ‘Quantityone’ software. Real-time RT-PCR analysis of cytokine 
mRNAs was done using the RT2 qPCR primers with the SYBR green quantitative 
real-time PCR technology (SuperArray Bioscience Corporation). The SYBR green 
PCR master mix (Promega Corporation) was used to set up the reaction in a Corbett 
research thermal cycler with the following program: 95ºC, 15 min; 40 cycles of (95 
ºC, 30 sec; 55 ºC, 30 sec; and 72 ºC, 30 sec). GAPDH and 18s rRNA were used for 
normalization. For ELISA quantification of secreted cytokines, the Quantikine® kits 
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from R&D systems Inc., and the Biotrak system from Amersham Biosciences, were 
used. 
 
2.14 Preparation of whole cell lysates 
Cells were washed once with ice-cold PBS and lysed in lysis buffer [50 mM 
Tris·Cl, pH 8.0; 150 mM NaCl; 0.02% sodium azide; 1% Triton X-100 and freshly 
added protease inhibitor (Roche Applied Science)] on ice for 30 min and subjected to 
centrifugation at 14,000 rpm for 30min at 4°C. The supernatant was collected and the 
protein concentration was measured.  
 
2.15 Preparation of nuclear extracts 
Panomics nuclear extraction kit was used to fractionate the nuclear lysate. 
Briefly, the cells after treatment were washed with PBS twice and lysed with Buffer 
A for 10 minutes at room temperature. After centrifugation, the supernatant was 
saved as the cytosol fraction and the pellet lysed in Buffer B for 2 hours at 4ºC to 
obtain the nuclear fraction. 
 
2.16 Co-immunoprecipitation 
Modified RIPA buffer (Bidere et al., 2006) for THP1/U937 cells (50mM Tris pH 7.4, 
150 mM NaCl, 1mM EDTA, 1% NP-40, 1% deoxycholic acid, 0.1% SDS with 
‘complete’ Roche protease inhibitor without EDTA tablet-1 per 25 ml) was used to 
immunoprecipitate the TRAF-6/Caspase-4/IRAK1 complex, and the protocol from 
the laboratory of S. Barthomelew (freely available on the internet 
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http://pingu.salk.edu/~sefton/Hyper_protocols/immunoprecip.html ) was followed for 
immunoprecipitation. Briefly, cells were harvested in ice cold tubes, centrifuged and 
washed with ice-cold PBS followed by lysis in 500 µl THP1/U937 IP buffer or 293T 
IP buffer (Bidere et al., 2006) (50mM Tris pH 7.4, 150 mM NaCl, 2mM EDTA, 1% 
NP-40, 1% Triton X-100 with Roche protease inhibitor tablet without EDTA-1 per 25 
ml) for 20 minutes on ice, and the lysate cleared at 20000 x g for 30 minutes. After 
saving some for total lysate analysis and quantification, the remainder was used for 
incubating with the respective antibody for 1 hour on ice. 50µl of Anti-mouse IgG 
beads (Ebioscience) was added and incubated on a rocking platform in the cold room 
for 2 hours. After at least 3-4 washes with 1 ml of the respective lysis buffer, the 
beads were stored dry at -20ºC till further analysis. Freshly prepared sample buffer 
with DTT was used to solubilize the proteins and after boiling for 3 minutes followed 
by centrifugation, the sample was immediately loaded and analyzed by SDS-PAGE 
and Western transfer. The Mouse TrueBlot™ western blot kit (eBIOSCIENCE) 
protocol was used to mask the heavy and light chains of the antibody in the developed 
blot. 
 
2.17 Short hairpin RNA targeting of caspase-4  
Small interfering RNAs (siRNAs) are short double-stranded RNA molecules 
that can target complementary mRNAs for degradation via a cellular process termed 
RNA interference (RNAi) (Elbashir et al., 2001).  
Small hairpin RNA (shRNA) is the convenient system developed to target 
siRNA into the cells by a having a 19-mer loop connecting the sense and the 
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antisense strand, thereby increasing the efficiency of targeting. For cloning into the 
vector, shRNA inserts have the advantage of only a single pair of oligonucleotides 
and a single ligation step.  
I used Ambion’s pSilencer hygro expression vectors that feature a human U6 
RNA polymerase III promoter and a hygromycin resistance gene to enable antibiotic 
selection. Target sites in caspase-4 for designing shRNAs to knock down casp-4 were 
considered only in regions common to all the major isoforms of caspase-4 that lacked 
any homology to other proteins in the human or mouse genomes (Figure 3.1). This 
common region was compiled together and analyzed with the siRNA target finder 
software at www.ambion.com. Six different oligonucleotide sequences with less than 
50% GC content were chosen for the siRNA-mediated knock-down of casp-4. The 
hairpin shRNA-encoding oligonucleotides were synthesized along with the loop 
sequence TTCAAGAGA and ligated into the BamH I and Hind III restriction sites 
(added to the 5’ and 3’ end of the DNA oligonucleotides respectively) for cloning into 
the vector. The vector was sequenced to confirm the integrity of the cloned sequence 
before transfecting in the selected cell lines. 
 











Table 2.3 List of oligonucleotides used for caspase-4 knock-down. The oligos that 
were effective in knocking down the expression are marked in bold. 
 
 Starting Position in Caspase-4 
in alpha, gamma and delta   
mRNA respectively 
Sequence (5’ to 3’) 
1 377, 410, 385 (AA)TCTACAGATGCCCTCAAGC 
2 667, 700, 675 (AA)GTCCTCTGACAGCACATTC 
3 902, 910, 935 (AA)GTGGCCTCTTCACAGTCAT 
4 1026, 1059, 1034 (AA)TGGGCTCTATCTTCATCAC 
5 1163, 1196, 1171 (AA)CGACTGTCCATGACAAGAT 
6 1252, 1285, 1260 (AA)GGAGCACCTTCATTAGTAC 
 
 
In the first instance, oligonucleotides 4, 5, and 6 were employed, and 
oligonucleotides 5 and 6 were very effective in reducing the expression of caspase-4 
in the cell lines tested. 
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3. CHAPTER 3. Caspase-4 plays a role in ER stress-
mediated apoptosis and polyglutamine aggregate-
induced apoptosis 
 
3.1 Caspase-4 levels are massively reduced in shRNA knockdown 
stable clones 
By using the shRNA vector expressing the oligonucleotide 6 (refer to chapter 3, 
section 2.17) against all the three isoforms of caspase-4 mRNA and stable selection 
with the hygromycin antibiotic, four independent stable clones with substantial 
knockdown in basal caspase-4 protein levels was obtained (Fig. 3.1). As shown in 
Figure 3.1 caspase-4 levels were considerably reduced in SHEP1 cells, enabling me 
to analyze the role of caspase-4 in apoptosis. 
 
                           






Figure 3.1 Stable knock-down of caspase-4 in SHEP1 cells.  
The stable shRNA stable clones are denoted as SA, SB, SC, and SD. WT and VC are the wild 
type and vector control expressing the shRNA against nonsense sequence respectively. 
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3.2 Caspase-4 is not involved in the major extrinsic and intrinsic 
apoptotic pathways 
Caspase-4 knockdown clones and wild-type SHEP1 cells were treated with 
different apoptotic inducers for 24 hours before subjecting them to cell viability 
analysis by the WST method. Before proceeding with the experiment, the wild-type 
cells were subjected to these different stimuli to determine the dose and to confirm 
that the cells die mainly by apoptosis (by sytox-hoechst staining – data not shown). 
The intrinsic mitochondrial cell death pathway inducers, staurosporine, etoposide, 
camptothecin and doxorubicin induced around 100%, 75%, 50% and 48% cell death, 
respectively, in both the control (wild type and vector control) as well as the caspase-
4 knockdown stable clones (SA, SB) after 24 hours of treatment. The extrinsic death 
receptor pathway activators, TRAIL, TNFα and Anti-Fas also elicited the same 
amount of cell death (65%, 85%, and 50%, respectively) in the controls and caspase-4 
knockdown clones. The transcription inhibitor actinomycin D as well as the 
translation inhibitor cycloheximide also induced cell death to the same extent (40% 
and 80%, respectively) in both the control and caspase-4 knockdown clones. Figure 
3.2 summarizes these results in a graphical format after grouping together the wild 
type and vector control values [as controls] and the two caspase-4 shRNA knockdown 













Figure 3.2 No changes in the levels of apoptosis in caspase-4 knockdown cells 
with common apoptotic inducers. SHEP1 clones SA and SB with reduced caspase-4 
expression along with wild-type and shRNA negative controls were subjected to different 
types of stress to induce apoptosis using 5 µM staurosporine, 0.1 µg/ml Anti-Fas, 1 µg/ml 
TRAIL, 10 µM etoposide, 10 µg/ml cycloheximide,  10 µM camptothecin, 0.1 µg/ml TNFα 
in the presence of  1 µg/ml cycloheximide, 5 µM doxorubicin and 2 µg/ml actinomycin D for 
24 hours, and cell proliferation was assayed by the WST method. The results are represented 
in inverse as percentage cell death based on the untreated population, and the controls and 
clones were grouped together as bars representing the mean ± S.E.   
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Figure 3.3 Localization of caspase-4 in ER. SHEP1 cells were transfected with eGFP-
tagged caspase-4 and grown in chamber slides before subjecting to fixing and staining. eGFP-
tagged caspase-4 is depicted by the green colour visible in the first column. The cytoplasmic 
marker tubulin, Golgi marker GM130, mitochondrial marker cytochrome c, ER marker 
Calreticulin are all counter-stained with a red fluorescent antibody as depicted in the second 
column. The third column of panels shows the merged picture of the respective marker with 
caspase-4. 
 
3.3 Caspase-4 is localized mainly to the endoplasmic reticulum 
The subcellular localization of a protein could indicate the site of its action. 
Hence, I studied the localization of transfected caspase-4 in SHEP1 wild-type cells. 
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When caspase-4 fused with GFP at its COOH terminus was overexpressed in SHEP1 
neuroblastoma cells to assess its subcellular localization, most of the fluorescent 
signals from the caspase-4/GFP fusion protein overlapped with those of the ER 
marker calreticulin (figure 3.3 - 4th row), and the cytosol marker tubulin (fig. 3.3 – 1st 
row) confirming earlier reports (Hitomi et al., 2004) that caspase-4 is an ER resident 
protein. There was no overlap with either the golgi marker GM130 or the 
mitochondrial marker cytochrome c (fig. 3.3, 2nd and 3rd row, respectively). It can be 
concluded that caspase-4 predominantly co-localizes with the ER and the cytosol.  
 
3.4 ER stressors and apoptosis 
To confirm that the selected agents indeed induce ER stress under the chosen 
conditions, SHEP1 wild type cells were subjected to these stressors for 0, 2, 4, 8, and 
24 hours, and the cells lysed to examine the up-regulation of the classical marker of 
ER stress, GRP78/Bip. Tunicamycin at 5µg/ml induced GRP78 around 8 hours which 
continued to increase to much higher levels after 24 hours of treatment, showing that 
ER stress is induced upon tunicamycin treatment (fig 3.4A). Similarly, BFA 
(Brefeldin A) at 10 µg/ml induced ER stress by 24 hours; Thapsigargin at 5 µM and 
A23187 at 5 µM induced ER stress by 8 and 24 hours, respectively (Fig. 3.4A). As 
negative controls, the mitochondrial pathway stressor, doxorubicin and receptor 
induced death agonist, anti-Fas did not induce GRP78. 
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Figure 3.4 ER stress reagents induce cell death by apoptosis and up-regulate the 
ER stress marker GRP78. (A) SHEP1 wt cells were treated with different reagents as 
indicated (tunicamycin 5µg/ml; BFA 10µg/ml; Anti-Fas 1µg/ml; thapsigargin and A23187 
5µM each; and doxorubicin 5µM) and after 0, 4, 8 and 24 hours of treatment; cells were 
harvested, lysed and subjected to Western blot to visualize the GRP78 chaperone protein. 
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Actin serves as loading control in the bottom panel. (B) SHEP1 wt cells were subjected to 
different cell death inducers (at the same concentrations as in A); stained with Sytox-Hoechst 
and observed under the fluorescent microscope after 24 hours. 
 
To investigate whether these ER stressors induce cell death mainly by 
apoptosis, the SHEP1 cells were subjected to these stressors and the cell morphology 
observed by sytox-hoescht staining (Figure 3.4B). All four ER stress-inducing 
chemicals along with the positive control anti-Fas, induced cell death mainly by 
apoptosis as indicated by the classical apoptotic morphology of nuclei condensation 
and break down of the cell into small rounded apoptotic bodies. This was further 
reinforced by the blue staining of these bodies that shows that their membrane is 
intact and sytox cannot penetrate the cells (necrosis would involve the disintegration 
of the membrane and the seepage of the green sytox stain). The first panel shows the 
untreated SHEP1 cells stained blue by Hoechst 33342 as this stain is able to permeate 
the membranes and viability is depicted as the whole cell without apoptotic bodies. 
 
3.5 Caspase-4 is processed in response to ER stress 
As the substrate(s) of caspase-4 is unknown, another way to determine the 
involvement of caspase-4 in a particular pathway is by assessing the activation of 
caspase-4 as indicated by the processing of the enzyme and the resultant cleavage 
products. SHEP1 cells were treated with tunicamycin and BFA for 0, 8, 18, and 24 
hours, and the lysate analyzed for reduction in pro-caspase-4 levels, which indicates 
the processing and hence activation of pro-caspase-4 into smaller fragments. 
Tunicamycin treatment activates caspase-4 as early as 8 hours after treatment, while 
 73
BFA induces procaspase processing by 18 hours, indicating that both these ER 
stressors induce caspase-4 activation (Figures 3.5A and B). Figure 3.5C shows the 
cleaved caspase-4 fragment appears only after ER stress induction and not with the 
negative controls, anti-Fas and doxorubicin. Tunicamycin at 5µg/ml induces caspase-
4 processing and the appearance of p20 active form around 8 hours after treatment 
and continues until 24 hours following treatment. BFA at 10 µg/ml induces the 
processing of caspase-4 around 24 hours after treatment as evidenced by the 
appearance of the p20 active form. Thapsigargin also activates procaspase-4 earlier at 
8 hours similar to tunicamycin, and A23187 activates the caspase-4 late as shown by 
the appearance of the active form around 24 hours of treatment, similar to the BFA 
profile. The negative ER stress controls, Anti-Fas and doxorubicin do not induce any 
processing of procaspase-4 or lead to the appearence of the p20 cleavage product. 
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Figure 3.5 Caspase-4 is processed in response only to ER stress. (A) SHEP1 cells 
were treated with either 5µg/ml tunicamycin or 10µg/ml BFA for the indicated times (hours), 
and the pro-caspase-4 levels estimated by western blot. (B) densitometric volume 
quantification and representation in graphical format of the data in A. (C) SHEP1 cells were 
treated with 5µg/ml tunicamycin; 10µg/ml BFA; 1µg/ml Anti-Fas; 5µM each of thapsigargin, 
A23187 and doxorubicin for the indicated times, and the lysate analyzed by western blot for 
the cleaved caspase-4 fragment.  
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3.6 Involvement of caspase-4 in ER stress-induced apoptosis 
Caspase-4 knockdown stable clones (SA, SB, SC, SD) were subjected to 
tunicamycin-induced apoptosis for 24 hours, and cell viability was assessed by the 
WST method. The shRNA stable clones were 10 to 30% more viable compared to the 
control clones, implicating a role for caspase-4 in tunicamycin-induced apoptosis 
(Figure 3.6A). BFA treatment (10 µg/ml for 24 hours) showed that caspase-4-
deficient clones were 10% to 25 % more viable compared to the controls with intact 
caspase-4 (Figure 3.6B). Thapsigargin treatment at 5 µM for 24 hours followed by 
cell death assay by the LDH release method showed that the control cells underwent 7 
to 10% more cell death compared to the caspase-4-deficient clones (Figure 3.6C). 
Similarly, A23187 (calcium ionophore) treatment followed by LDH assay after 24 
hours showed that the caspase-4 knockdown clones were protected from cell death by 











































































Figure 3.6 Caspase-4 knockdown protects cells against ER stress-induced 
apoptosis. The SHEP1 stable clones with shRNA for caspase-4 (SA, SB, SC, SD) along 
with the controls (WT and VC) were subjected to different types of ER stress and cell death 
was quantified either directly by LDH assay or indirectly by the WST method. Results show 
cell survival after (A) Tunicamycin at 5µg/ml for 24 hours by WST assay; (B) BFA at 
10µg/ml for 24 hours by WST assay and cell death after (C) 5µM thapsigargin for 24 hours 
by LDH assay, and (D) 5µM of A23187 for 24 hours by the LDH method. The bars represent 
the mean ± S.E. of triplicate treatments. 
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3.7 ER stress induces G2/M arrest preferentially in the caspase-4-
deficient SHEP1 cell population. 
FACS analysis of wild-type SHEP1 cells and the caspase-4 knockdown clones 
after treatment with ER stress inducers revealed an interesting observation. Under 
normal circumstances, the cell cycle distribution of the population of wild-type and 
vector control cells was no different from caspase-4 knockdown clones. Most of the 
population was in the G1 cell cycle phase and 10-22% of the population in G2/M 
phase (figure 3.7A). However, after treatment with the ER stress inducers there was a 
distinct difference in the profile of cell cycle stages between the caspase-4 
knockdown clones and the controls (Figure 3.7B). Treatment with tunicamycin at 
5µg/ml for 24 hours resulted in 4-6.9% of the control population being in the G2/M 
phase, while the caspase-4 down-regulated clones showed an increase ranging from 
8.7-15% in this subpopulation of G2/M phase cells (figure 3.7C). Similarly, treatment 
with BFA at 10µg/ml resulted in an accumulation of 7.9-15% of the population in the 
G2/M phase in the caspase-4 knockdown clones compared to only 3-4% of the 
control population (Figure 3.7D). The calcium channel inhibitors, thapsigargin and 
A23187 showed even more pronounced differences in the G2/M arrested population. 
In the case of 5µM thapsigargin, 13-25% of the population was in G2/M phase in the 
caspase-4 knocked down clones, and after A23187 treatment for 24 hours, 20-43% 
cells were arrested in the G2/M phase compared to 5-10% of the control cells 
(Figures 3.7E and 3.7F). This phenomenon of the caspase-4 knockdown cells with 
respect to the accumulated G2/M population after treatment was unique to ER stress 
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reagents as evidenced by the lack of difference in the subpopulations after anti-Fas 
treatment for 24 hours (Figure 3.7G ).  
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Figure 3.7 Caspase-4 knockdown results in G2/M arrest following treatment 
with ER stressors. A to G (except B) show the result of FACS analysis after sorting by 
propidium iodide staining using the BD-FACS-calibur (BD biosciences). The histogram was 
drawn showing the two peaks – the first major peak is the G1 phase of cell cycle and the 
second minor peak is the G2/M phase where the cells are either preparing to undego mitosis 
or are in the mitotic phase of division. These peaks are differentiated based on the amount of 
DNA in the sample – 2n or 4n. In all these figures, the number depicted in bold (M3) is the 
percentage of cells in G2/M phase of the cycle. The four caspase-4 shRNA knockdown 
clones along with the wild-type and vector control were treated with 5µg/ml tunicamycin (C); 
10µg/ml BFA (D); 5µM thapsigargin (E); 5µM A23187 for 24 hours, and the cells harvested 
for staining. (A) represents the untreated control samples. (B) illustrates the summary of these 
data showing the population arrested in the G2/M phase. The bars are grouped as caspase-4 





3.8 Involvement of caspase-4 in polyglutamine aggregate-induced ER 
stress 
                                     
PolyQ(11) PolyQ(72)
 
Figure 3.8: PolyQ(72) induces cell death by apoptosis. SHEP1 cells transfected with 
either poly(Q)11 or poly(Q)72 tagged with GFP were observed 36 hours after transfection 
using a fluorescent microscope to analyze the typical apoptotic morphology. 
 
Polyglutamine (PolyQ) aggregates are toxic to certain types of cells when they 
exceed a certain length and underlie many neurodegenerative disorders. In the SHEP1 
neuroblastoma line, the susceptibility to Poly(Q)-induced cell death was investigated 
by transiently transfecting the cells for 48 hours with either the non-toxic Poly(Q)11 
or the pathological Poly(Q)72 repeat-containing plasmid tagged with eGFP. The 
positively transfected cells glow green under the fluorescent microscope and by 
analyzing the morphological features, the state of the cell was determined. Figure 3.8 
shows the fluorescent micrograph of the transfected cells. Poly(Q)72 transfected cells 
show typical apoptotic morphologies with condensed nuclei and fragmentation into 
small apoptotic bodies, whereas the poly(Q)11 transfected cells are healthy - 
indicating that SHEP1 cells are susceptible to expanded poly(Q) aggregate-induced 
cell death, and the cell death occurs mainly by apoptosis.  
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To proceed with further experiments, enrichment of the transfected cells was 
essential to generate a uniform population. As the plasmids were GFP-tagged, this 
was used as a marker to sort by FACS the positively-transfected cells (Figure 3.9A). 
After enrichment, these cells were used for analyzing whether poly(Q)72 aggregate-
induced apoptosis involves ER stress. The hallmark of ER stress, GRP78/Bip 
upregulation, was checked in the enriched cell lysate by western blot. Figure 3.9B 
shows that only the long pathological form of Poly(Q)72 aggregate up-regulates 
GRP78, while the short non-toxic form does not. The next step was to check the 
involvement of caspase-4 in this ER stress-induced apoptosis. By using a specific 
antibody that recognizes the cleaved form of caspase-4, the processing and hence 
activation of caspase-4 was detected only with the transfection of the poly(Q)72 
aggregate-expressing plasmid (Figure 3.9C). 






















             
Figure 3.9: Polyglutamine aggregates induce ER stress and caspase-4 processing. 
(A) Enrichment of positively transfected SHEP1 cells by FACS, showing the results for 
poly(Q)11- and poly(Q)72-transfected cells.(B) GRP78 upregulation after different 
transfections for 24 hours. (C) processed p20 cleaved form of caspase-4 after transfections 
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Figure 3.10 Caspase-4 is involved in polyglutamine aggregate-induced apoptosis. 
(A) Apoptosis as observed under the fluorescent microscope after 48 hours of transfection 
with either poly(Q)11 or poly(Q)72 in caspase-4 knockdown clones (SB, SC) along with the 
controls (WT, VC). More rounded and floating apoptotic cells after poly(Q)72 treatment and 
comparatively more in the controls (B) Quantification of the apoptotic cells at 24 and 48 
hours following transfection. Control eGFP alone was used as a negative control. The bars 
represent the mean ± S.E. of at least 10 fields of observation.  
 
To confirm the role of caspase-4 in polyglutamine induced cell death, the 
caspase-4 knockdown clones and the appropriate controls were transfected with 
poly(Q)72-expressing plasmid or the controls, GFP alone or poly(Q)11 repeat-
expressing plasmid for 24 and 48 hours. Cell death was quantified based on apoptotic 
morphology at 24 and 48 hours following transfection. Figure 3.10A shows the 
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fluorescent micrographs illustrating the effects of different length poly(Q) transcripts. 
Poly(Q)11-transfected clones as well as controls did not show hallmarks of apoptosis 
On the other hand, poly(Q)72 transfected controls showed the characteristic 
morphology of rounded shrinking cells compared to the caspase-4 knockdown clones, 
SB and SC. The quantification of apoptotic morphology of the micrographs showed 
that caspase-4 knockdown clones were protected by at least 8-17% more compared to 
the controls expressing normal amounts of caspase-4 at 24 hours after transfection 
(Figure 3.10B, top panel). Caspase-4 knockdown clones, SB and SC were protected 
from polyglutamine aggregate induced apoptosis by 10-25% compared to the controls 
at 48 hours ( Figure 3.10B bottom panel) following transfection. 
                              
3.9 Discussion. 
Caspases play a central role in apoptotic cell death processes. When the cell 
experiences stress, and the repair/refolding mechanisms are overwhelmed, the 
caspase zymogens are activated to initiate cell death. Various types of cellular 
stresses activate a different complement of caspases that initiate and execute the 
apoptotic process. Virtually all types of extracellular and intracellular stress that result 
in apoptosis have been shown to involve one or more particular caspases. One initial 
focus in the apoptosis field was the engagement of death receptors and the use of 
DNA damaging agents. Later, mitochondrial stress induced by various treatments 
gained more attention (Szegezdi et al., 2003). Recently, the endoplasmic reticulum 
has been proposed to be a critical regulator of cell death with its central role in 
activating the unfolded protein response (UPR). It has been known that apoptotic 
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morphological changes are observed in cell death caused by ER stress (Imaizumi et 
al., 2001). However no specific human caspase had been implicated in this ER stress. 
With a report on the role of caspase-12 in ER stress-mediated apoptosis in mice 
(Nakagawa et al., 2000), the search commenced for the human counterpart that 
functions in ER stress-mediated apoptosis. Caspase-4 was then shown (Hitomi et al., 
2004) to be the human counterpart with regard to its involvement in ER stress-
mediated apoptosis induced by β-amyloid protein. Now, I confirm that caspase-4 
plays a role in ER stress-mediated apoptosis, and show for the first time that this 
caspase likely contributes to ER stress-mediated apoptosis induced by expanded 
poly(Q) repeats.  
The predominant localization of caspase-4 in the ER and its activation only 
with ER stress-inducing agents and not with any conventional apoptosis inducers 
reinforces the role of caspase-4 in ER stress-mediated apoptosis. There was an initial 
report that caspase-4 might be involved in anti-Fas-induced apoptosis (Kamada et al., 
1997). But here I show that caspase-4 is neither activated (as shown by lack of its 
processing) nor involved in cell death induced by anti-Fas (as shown by the absence 
of protection from cell death in caspase-4 knockdown clones), excluding any role for 
caspase-4 in fas ligand-induced cell death in SHEP1 cells.  
The modest levels of protection observed in the caspase-4 knockdown clones 
(only 10-30%) could be due to incomplete knockdown of caspase-4, as longer 
exposures of the images in figure 3.1 show a low level of caspase-4 (data not shown). 
Low levels of caspase-4 in the knockdown clones could still mediate some ER stress-
related apoptosis, because caspases participating in cell death undergo auto-
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proteolytic processing with a subsequent amplification reaction involving the 
activation of downstream caspases and cleavage of other substrates. The other 
possibility is that caspase-4 is not the only protease involved in ER stress-mediated 
apoptosis and other caspases might also be concurrently involved in this process. 
Nevertheless, I have used four independent caspase-4 knockdown clones to 
comprehensively examine their sensitivities to a broad range of cell death inducers, 
and conclude that caspase-4 does play a contributory role specifically in ER stress-
mediated apoptosis. Importantly, I show that the levels of protection seen with 
shRNA experiments are comparable to those reported for the caspase-12 knock-out 
mice (Nakagawa et al., 2000). 
The cell cycle denotes the highly regulated phases a cell passes through in its 
growth and division into daughter cells. Cell cycle checkpoints help ensure the 
progression through these phases and any damage or stress to the cell results in cell 
cycle arrest at these checkpoints (DiPaola, 2002). In the G1 phase, cells commit to 
enter the cell cycle and replicate their DNA in S phase. When cells enter the G2 
phase, repair might occur along with preparation for mitosis in M phase (DiPaola, 
2002). One theme emerging in drug discovery is to develop agents targeting the cell-
cycle checkpoints that are responsible for the control of cell-cycle progression. For 
example, defects in the G2/M arrest checkpoint may allow a damaged cell to enter 
mitosis and undergo apoptosis, and efforts to enhance this effect may increase the 
cytotoxicity of chemotherapy (DiPaola, 2002). Enhanced accumulation of the 
caspase-4 knockdown cells at the G2/M checkpoint indicates a possible requirement 
for caspase-4 in traversing or somehow regulating the G2/M checkpoint. It may be 
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speculated that caspase-4 contributes to ER stress-induced apoptosis either by 
suppressing time spent in G2/M repair of cellular damage caused by ER stressors, or 
alternatively, in permitting cells damaged by ER stress to traverse too quickly to M 
phase and undergo apoptosis instead of division. However, much more needs to be 
done to address these possibilities. Mine is the first report in mammals indicating that 
ER stress inducers might regulate G2/M arrest. However, there is a precedent in the 
budding yeast, Saccharomyces cerevisiae; treatment of yeast cells with ER stress 
inducers like tunicamycin, miconazole or other inhibitors triggered a transient G2/M 
arrest (Bonilla and Cunningham, 2003).  
As the aggregates of malformed or misfolded proteins have the inherent 
characteristics of an ER stress inducer, I first investigated whether the ER stress UPR 
pathway is activated under these conditions, and secondly whether caspase-4 is 
involved in such a scenario. By establishing a polyglutamine tract-expressing system 
in susceptible cells, my experiments showed that the toxic long form of a 
polyglutamine repeat protein caused ER stress and subsequent apoptosis involving the 
activation of caspase-4. The role of caspase-4 in polyglutamine aggregate-induced 
apoptosis was confirmed as the caspase-4 knockdown clones were (10-25%) less 
susceptible to cell death compared to caspase-4-expressing controls in the presence of 
polyglutamine aggregates. Hence, activation of caspase-4 may represent one of the 
apoptotic pathways induced by poly(Q)72 aggregates. 
Evidence suggests that although polyglutamine tracts themselves are very 
toxic, the sequence outside this tract defines the course of the particular disorder (Orr, 
2001). If initiation and progression of each of the diseases ends up being as tightly 
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linked to the normal function of the protein as has been suggested for SCA6 
(Restituito et al., 2000), it becomes less likely that a common mechanism of 
pathogenesis will ensue. In this case, therapeutic efforts would best be directed at the 
enhancement of cellular protective measures. The molecular chaperones and the 
proteosomal complex are likely to play an important role in protecting a neuron 
against the deleterious effects of an expanded polyglutamine tract. Perhaps the late 
onset typically seen with these disorders is due to the protective mechanisms 
becoming overwhelmed with time. Targeting caspase-4, which is involved in 
apoptosis initiated by poly-glutamine aggregates might result in providing more time 
for the UPR machinery to operate and rescue the cell from polyglutamine stress and 
neuronal loss. Hence, drugs targeting caspase-4 in combination with agents that 
facilitate the elimination of misfolded proteins could provide for an effective 




4. CHAPTER 4. Caspase-4 in innate immunity: Caspase-
4 interacts with TRAF6 and mediates LPS-induced 
NF-κB activation and IL-8 and MIP-1β production 
4.1 Stable knock down of caspase-4 in the human monocytic cells, 
THP1 
  A substantial knockdown in basal caspase-4 protein levels was observed in 
four independent stable clones (Fig. 4.1). In contrast, the yield of caspase-8 remained 
essentially the same in all four clones (Fig. 4.1), which as discussed later is 
significant  as caspase-8 has been shown to be involved in both innate and adaptive 
immunity through NF-κB activation (Beisner et al., 2005; Su et al., 2005; Beisner et 
al., 2005; Salmena et al., 2003).  
              







Figure 4.1 Stable knockdown of caspase-4 in the human monocytic cell line, 
THP1 Western Blot. Top panel, stable and efficient knockdown of caspase-4 by shRNA in 
four independent THP1 clones (TA, TB, TC, TD). The parental clones are denoted as WT, 
and the vector control (VC) clones stably express shRNA against a scrambled sequence. 
Middle panel, Western Blot probed with a caspase-8 antibody. 
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4.2 Defects in secreted cytokines in the caspase-4 knockdown clones 
Caspase-4 belongs to a group of caspases involved in inflammation, and hence 
I investigated the role of this caspase in cytokine production. Caspase-4 knockdown 
and control caspase-4-expressing cells were treated with LPS (a TLR4 inducer) for 8 
h and the pattern of 72 secreted cytokines and chemokines was examined using a 
semi-quantitative commercial antibody array. Knockdown of caspase-4 altered the 
yields of several extra-cellular cytokines (including some chemokines) after TLR4 
induction with LPS - notably IL-8 and MIP-1β highlighted in figure 4.2A, and MCP-
1, IFNγ, HGF, EGF, RANTES and NAP-2 (data not shown). The amounts of IL-8 
and MIP-1β identified in the culture supernatant were markedly suppressed (by 1.7-
fold for both) in the caspase-4 knockdown clone after LPS treatment (Fig. 4.2A). The 
reduction in extra-cellular IL-8 and MIP-1β protein levels in the caspase-4 
knockdown clones was confirmed and quantified using an ELISA assay, which 
showed a 5- and 6-fold reduction in immuno-reactive IL-8 and MIP-1β, respectively 
(Fig. 4.2 B1 and B2). A similar substantial reduction in extra-cellular MIP-3α was 
observed in the caspase-4 knockdown clones (Fig. 4.2 B3) despite the fact that the 
amount of immunoreactive MIP-3α protein was below the level of detection on the 
array. Together, these results suggest the possibility that caspase-4 has a role 
upstream of secretion of certain inflammatory cytokines induced by LPS. 
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Figure 4.2 Defects in secreted cytokines in the caspase-4 knockdown clones. (A) 
THP1 parental (WT, upper panel) and caspase-4 knockdown shRNA clone cells (TC, lower 
panel) were treated with LPS for 8 hours, and the supernatants were subjected to the ‘Raybio’ 
protein array to analyze the secretion pattern of 72 cytokines. The IL-8, and MIP-1β spots, 
highlighted in octagons, were scanned by densitometry, and the intensities of the spots were 
compared before and after LPS treatment. (B1, B2, B3) ELISA assays to quantify and 
compare IL-8, MIP-1β and MIP3α in the culture supernatants of THP1 clones. Caspase-4 
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knockdown clones (TA, TB, TC, TD) along with THP1 wild-type and vector control cells 
were treated with LPS for 8 hours, and the supernatants were used to quantify the IL-8 levels 
(B1), MIP-1β levels (B2) and MIP-3α (B3). Data are grouped together as ‘control’ 
comprising WT and VC, and ‘clones’ comprising the four caspase-4 shRNA clones, and 
represented as mean ± S.E. The two-tailed t test gives a P value < 0.001 for B1, B2 and B3. 
 
4.3 Reduced LPS-stimulated up-regulation of specific cytokine 
mRNAs in caspase-4 knockdown cells 
Cytokines are tightly regulated at three major steps (Burns et al., 2003b; 
Martinon et al., 2006) - transcription, processing and secretion. Caspase-1 plays an 
essential role in the processing of cytokines like IL-1β, IL-18 and IL-33 (Akita et al., 
1997; Schmitz et al., 2005; Thornberry et al., 1992). I investigated the step at which 
caspase-4 might participate in regulating cytokine production by employing semi-
quantitative RT-PCR to determine whether the knockdown in caspase-4 had any 
effect on LPS-induced mRNA yields of a wide spectrum of cytokines and 
chemokines. Fig. 4.3A and 4.3B show that following LPS stimulation for 4h, six out 
of the 15 tested mRNAs (IL-1β, IL-6, IL-8, IL-12B, MIP-1β and MIP-3α) all 
exhibited a 50% or greater reduction after LPS stimulation in four independent 
caspase-4-deficient clones compared to the parental and vector control cells. The 
remaining mRNAs encoding IL-18, MMP2, IL-2, IL-4, IL-5, IL-10, IFN-γ, and MCP-
1 showed no such reduction (Fig. 4.3A, B). I chose IL-8 and MIP-1β for further 
studies, because their mRNAs and secreted proteins were present in substantially 
lower yields in the caspase-4 knockdown clones as judged by both the RT-PCR 
quantification (Fig. 4.3B), antibody array (Fig. 4.2A), and ELISA assay (Fig. 4.2B1 
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and B2). The reason why IL-1β and MIP-3α was not recognized on the raybio array 
in figure 4.2A could be due to lower sensitivity of the blot. In the case of IL-1β, an 
additional signal (like ATP) is needed for the secretion of the cytokine (Mariathasan 





































































Figure 4.3 Reduced LPS-stimulated yields of specific cytokine mRNAs in 
caspase-4 knockdown cells. (A) Each panel shows the LPS-stimulated mRNA level of a 
different cytokine mRNA as judged by RT-PCR and separated by agarose gel electrophoresis. 
From left to right: parental (WT), TA, TB, TC, TD caspase-4 knockdown, and vector control 
(VC) THP1 cells after LPS treatment for 4 h. The panels marked with * on the left side 
indicate the cytokine mRNAs that are down-regulated in the caspase-4 knockdown clones. 
(B) Quantification by densitometry of selected mRNAs that appear to be down-regulated in 
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panel A (*). Black bars, cytokine mRNA levels in wild-type and vector control cells (WT, 
VC); white bars, cytokine mRNA levels in the caspase-4 knockdown clones. Data in B are 
represented as mean ± S.E. of the control or clones after grouping their respective 
densitometric volumes together. Two-tailed t tests were performed, and the P values are IL-
1β P=0.02; IL-6 P=0.07; IL-8 P=0.04; IL-12B P=0.02; MIP-1β P=0.01; MIP-3α P=0.04. 
To confirm the RT-PCR results and to verify that the decreased yields of the 
mRNAs for IL-8 and MIP-1β is due to a reduction in LPS-induced mRNA up-
regulation, we repeated the RT-PCR analysis both before and after LPS treatment of 
THP-1 cells and their caspase-4 knockdown counterparts (Fig. 4.4). Whereas there 
was no difference in the basal, untreated levels of IL-8 and MIP-1β, there were 
consistent ~50% reductions in both mRNAs following 4h of LPS stimulation in all 
the caspase-4-deficient clones (Fig. 4.4A, B).  A similar reduction in the mRNA for 
MIP-3α was observed in all the caspase-4 knockdown clones following LPS 
stimulation (Fig. 4.4C). To further verify these findings, we carried out quantitative 
real time RT-PCR, which clearly showed that IL-8 and CCL4 mRNAs were poorly 
up-regulated by LPS in the caspase-4-deficient cells compared with the wild type and 
vector control cells (Fig. 4B, D). Although TNF mRNA was only marginally reduced 
in the caspase-4 knockdown clones in the semi-quantitative RT-PCR, Q-PCR did 
confirm that TNF mRNA production is dependent in large part on caspase-4 (data not 
shown). Together with the other data in figures 4.3 and 4.4, these results indicate 
lower LPS-induced yields of some cytokine and chemokine mRNAs in a caspase-4-
deficient human monocytic cell line, and demonstrate that the reduced LPS induction 
of IL-8, MIP-1β and MIP-3α mRNAs mirrors the deficiency of their secreted proteins 
(Fig. 4.2B1, B2 and B3) under similar conditions.  
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Figure 4.4 Reduced LPS-stimulated up-regulation of specific cytokine mRNAs in 
caspase-4 knockdown cells. (A) Top panel: RT-PCR was used to detect IL-8 mRNA 
yields before (Untr) and after LPS treatment for 4 h. Lower panel: quantification of RT-PCR 
shown in left panel by densitometry after normalization against GAPDH. Controls, mean 
 97
values of parental and vector control cells. shRNA clones, mean values of caspase-4 
knockdown clones, TA to TD. The P values before and after LPS treatment were 0.66 and 
0.0003, respectively. (B) Real time RT-PCR quantification of IL-8 mRNA in WT, VC cells 
and the shRNA clones TB and TC, before and after 4 h of LPS stimulation. Values are mean 
± S.E. of two individual samples. P values were 0.05 for all the clones treated with LPS 
compared to both WT+LPS as well as VC+LPS. (C) Corresponding data for the LPS-induced 
up-regulation of CCL4 mRNA derived as in A. Since the internal control GAPDH primers 
are not compatible with the CCL4 primers, the GAPDH primer data from panel A was used 
for normalization. Values are the mean ± S.E. of the controls grouped together comprising 
WT and VC, and the caspase-4 shRNA group comprising the clones TA to TD. The P values 
before and after LPS treatment were 0.64 and 0.01, respectively. (D) Real time RT-PCR to 
quantify CCL4 mRNA before and after LPS stimulation of the same cells as in panel B. P 
values were 0.001 and 0.0005 for caspase-4 shRNA clones treated with LPS compared to 
WT+LPS and VC+LPS, respectively. E and F depict the CCL20 mRNA by RT-PCR and 










4.4 Caspase-4 mediates LPS-induced IL-1β production 
Although there was no detectable difference in the IL-1β secretion patterns between 
the caspase-4 knockdown clones and the caspase-4-expressing THP1 cells in the 
array, I observed a clear reduction in the levels of IL-1β mRNA in the caspase-4 
knockdown clones after LPS stimulation (Fig. 4.3A and B). This was confirmed by 
RT-PCR after LPS treatment of the parental, vector control and four caspase-4 
shRNA clones (Fig. 4.5A). To further verify these findings, we carried out real time 
RT-PCR, which clearly showed that IL-1β mRNA was only slightly up-regulated by 
LPS in the caspase-4-deficient cells compared with the wild type and vector control 
cells (Fig. 4.5B). IL-1β requires two distinct signals for its activation and release 
(Burns et al., 2003a; Mariathasan and Monack, 2007a). The first signal is triggered by 
LPS, and the second signal can be derived from the activation of cell surface 
purinergic receptors of the P2X7 subtype, for which ATP is the main endogenous 
ligand (Hogquist et al., 1991; Mariathasan and Monack, 2007b). Hence, after LPS 
stimulation for 6 and 8 hours, we treated the parental and caspase-4 knockdown cells 
either with or without 7µM ATP for 30 minutes before harvesting the supernatant for 
ELISA quantification of secreted IL-1β (Fig. 4.5C). The results confirm that ATP is 
required for IL-1β secretion, and indicate that caspase-4 deficiency compromises the 
synthesis and hence the ATP-dependent secretion of IL-1β (Fig. 4.5C). 
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Figure 4.5 Synthesis of IL-1β mRNA and secretion of IL-1β are compromised in 
caspase-4 knockdown clones. (A) Left panel, RT-PCR to determine IL-1β mRNA in 
untreated and LPS-treated (4h) samples of caspase-4 knockdown clones TA, TB, TC and TD 
along with the controls (WT, VC). Right panel, quantification of levels of up-regulated IL-1β 
mRNA after normalizing for GAPDH levels and averaging the controls (WT, VC) and 
caspase-4 knockdown clones. (B) Real time RT-PCR quantification of IL-1β mRNA in WT, 
VC cells and the shRNA clones TB and TC, before and after 4 h of LPS stimulation. P values 
were ≤0.05 and ≤0.01 for shRNA clones treated with LPS compared to WT+LPS and 
VC+LPS, respectively. (C) Secreted IL-1β levels as estimated by ELISA in the supernatants 
of caspase-4 knockdown clones (TB, TC) and the controls (WT, VC) at 6 and 8 h after LPS 
treatment (1µg/ml) in the absence or presence of 7µM ATP for 30 min. P values for both time 
points were ≤ 0.002.                       
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Figure 4.6. Reduced NF-κB activation and nuclear translocation of the p65 
subunit of NF-κB in caspase-4 knockdown cells. (A) NF-κB transcriptional activity 
determined by luciferase reporter activity 4 h after LPS stimulation of THP1 (WT) and two 
vector control cell lines (TVC4, TVC5), along with the four independent caspase-4 shRNA 
clones (TA to TD). Mean and standard error of triplicates of each treatment and transfection 
are represented as the fold induction after 4 hours compared to the zero time after 
normalization with renilla for the differential transfection efficiencies. Values are the mean ± 
S.E. of three independent transfections. Two-tailed t test analysis of the caspase-4 shRNA 
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clones against the three controls gave a p value of 4.79E-06. (B1) Delayed translocation of 
p65 NF-κB subunit to the nucleus was delayed and reduced in caspase-4 knockdown clones 
TB and TC compared to wild-type (WT) and vector control (TVC) THP1 cells as shown by 
confocal imaging of the NF-κB p65 subunit at different times after LPS stimulation. p65 is 
stained green with FITC-conjugated secondary antibody. The nucleus is stained blue with 
Hoechst 3334. (B2) quantification of means of at least six independent fields from two 
treatments for each time point. Statistical analysis using the two-tailed t test comparing the 
parental and vector controls against the two knockdown clones gave the following P values: 
0.4 before treatment; 0.09 at 5 min; 0.0008 at 15 min, and 2.5E-05 at 45 min after LPS 
treatment. 
4.5 Caspase-4 mediates LPS-induced cytokine induction through NF-
κB-dependent trans-activation 
LPS signaling through TLR4 converges mainly on NF-κB transcription factor 
activation and subsequent cytokine transcription (Trinchieri and Sher, 2007), (Akira 
and Takeda, 2004). Having provided evidence that caspase-4 is involved in the 
transcriptional up-regulation of certain cytokines and their mRNAs through the TLR4 
pathway, we examined whether caspase-4 is required for NF-κB activation. All four 
caspase-4 knockdown clones had markedly suppressed LPS-mediated induction of 
NF-κB activity as indicated by the >50% reduced reporter activity after LPS 
treatment. (Fig. 4.6A). This suppression was corroborated by confocal microscopy, 
which showed that nuclear translocation of the NF-κB p65 subunit was selectively 
compromised in the four caspase-4 knockdown clones at various times following LPS 
stimulation (Fig. 4.6B-1, quantified in Fig. 4.6B-2). The impaired nuclear 
translocation of the NF-κB p65 subunit was further confirmed by cell fractionation 
experiments, which demonstrated that LPS-induced p65 protein translocation was 
strongly impaired in all the caspase-4 knockdown clones compared to the caspase-4-
expressing parental and vector controls (Fig. 4.7A, quantification in lower panel).   
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Figure 4.7 Inhibited nuclear translocation of p65 subunit of NF-κB, reduced 
IκBα degradation and IKKβ phosphorylation, in caspase-4 knockdown cells. (A) 
Upper panel, Western blot comparing cytosolic and nuclear levels of NF-κB p65 subunit after 
LPS treatment for the various indicated times in control (WT, VC) and caspase-4 knockdown 
clones (TA to TD). The blot was re-probed with lamin B to control for the purity of the 
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nuclear fractions. Lower panel, densitometric quantification of the upper middle panel, in 
which the WT and VC nuclear p65 values (‘controls’) were combined, and the nuclear p65 
values (‘clones’) were also combined. The bars represent the mean ± standard error. Two-
tailed t test analysis of the caspase-4 shRNA clones and controls (WT+VC) gave P values of 
0.02 before treatment; 0.01 at 15 min; 0.003 at 30 min and 0.26 at 60 min of LPS treatment. 
(B) Wild type (left panel) and caspase-4 shRNA clones (right panel) were treated with LPS 
for the various indicated times, and the yield of IκBα was examined by Western blot with an 
IκBα phospho-specific antibody (P-IκBα, top panels) or an IκBα-specific antibody (IκBα, 
second row panels), or the yield of phosphorylated IKKβ (P-IKKβ) was estimated (third 
rows). The fourth and lower panels depict IKKα and IKKβ, which are involved in NF-κB 
signaling, to serve as loading controls. 
 
NF-κB p65 subunit translocation is usually preceded by the phosphorylation 
and degradation in the cytoplasm of IκBα, the inhibitor of nuclear translocation of the 
RelA (p65) subunit (Hoffmann et al., 2002). Whereas the LPS-induced 
phosphorylation of IκBα occurred strongly and at early times after LPS stimulation of 
caspase-4-expressing cells, there was inhibition of and delay in the phosphorylation 
and resultant degradation of IκBα protein in a caspase-4 knockdown clone (Fig. 
4.7B). IκBα phosphorylation requires the kinase activity of IKKα/β, which in turn 
needs to be phosphorylated for its activation. Consistent with the pattern exhibited 
above, IKKβ phosphorylation was almost completely absent in the caspase-4 
knockdown clones unlike in the control cells (Fig. 4.7B). As loading controls, IKKα 
and IKKβ protein levels remained unchanged over time (Fig. 4.7B).  
As indicated above, it is established that NF-κB-dependent transcription of a 
number of cytokine and chemokine mRNAs contributes importantly to the subsequent 
production of cytokines and chemokines including IL-8 (Akira and Takeda, 2004; 
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O'Neill, 2006; Trinchieri and Sher, 2007). To verify the role of NF-κB activation in 
IL-8 (and MIP-1β) signaling after LPS stimulation, we treated caspase-4-expressing 
THP1 cells with a NF-κB inhibitor BMS-345541, which showed that the transcription 
of mRNAs encoding IL-8 and MIP-1β (Fig. 4.8A) and the secretion of immuno-
reactive IL-8 and MIP-1β proteins (Fig. 4.8B) is markedly suppressed to un-
stimulated levels. As a control, U0126 a specific inhibitor of the MEK1/2 pathway, 
failed to suppress LPS-induced IL-8 and MIP-1β mRNA up-regulation or IL-8 and 
MIP-1β protein production (Fig. 4.8A and B). Altogether, these data are evidence that 
caspase-4 acts upstream of and is required for full NF-κB activation that in turn leads 
to intra-cellular IL-8 mRNA up-regulation and IL-8 protein production in the cell 




































































Figure 4.8. NF-κB inhibitor blocks LPS-induced up-regulation and secretion of 
IL-8 and MIP-1β. (A) Agarose gel. RT-PCR analysis of IL-8 and MIP-1β mRNAs after 
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LPS stimulation for 4 h in THP1 parental cells treated with a vehicle control (DMSO), or an 
NF-κB pathway inhibitor (IκB kinase inhibitor BMS345541), or MEK1 and -2 inhibitor 
(U0126). (B) ELISA quantification of IL-8 and MIP-1β levels in the THP1 culture 
supernatant after 4 h of LPS stimulation utilizing identical treatments as in A. Two-tailed 
statistical analysis comparing the effect of DMSO and the two inhibitors after LPS treatment 
gave the following values: P=0.002 for BMS345541 and P=0.07 for U0126 in the case of 
IL8, and P=0.002 for BMS345541 and P=0.98 for U0126 in the case of MIP-1β. 
 
 
4.6 Caspase-4 interacts with endogenous and transfected TRAF6 
LPS triggers TLR4 resulting in recruitment of the adapters MyD88 or MAL to 
the activated receptor, which in turn promotes the association of IRAK1 and TRAF6 
to activate a NF-κB signaling complex (Akira and Takeda, 2004; Trinchieri and Sher, 
2007; O'Neill, 2006). Co-immunoprecipitation experiments were performed with 
caspase-4, TRAF6 and IRAK1 antibodies to determine whether caspase-4 might be a 
part of this multi-protein signaling complex in THP1 and U937 monocytic cells. 
Following LPS stimulation, the interaction of endogenous caspase-4 with endogenous 
TRAF6 in THP1 cells was an extremely early event, peaking at 5-10 min after LPS 
stimulation before returning to uninduced levels at 60 min (Fig. 4.9A, upper panel). 
Further, there was a reproducible second peak of interaction starting at around two 
hours after LPS stimulation in THP1 cells. With U937 monocytic cells, there was also 
clear and strong interaction of caspase-4 and TRAF6 at 5 min after LPS stimulation 
(Fig. 4.9B, upper panel). As has been established previously (Cao et al., 1996), 
TRAF6 and IRAK1 were found to interact in THP1 and U937 cells following the 
expected kinetics of association from 5 to 20 min after LPS treatment (Fig. 4.9A, B). 
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Endogenous caspase-4 also interacted with IRAK1 in both cell lines, closely 
following the biphasic pattern of the TRAF6-caspase-4 interaction in THP1 cells (Fig. 
4.9A, B).           
However, the kinetics of the IRAK1-caspase-4 interaction was slightly 
delayed compared to the caspase-4-TRAF6 association (Fig. 4.9A, B), suggesting that 
the TRAF6-caspase-4 interaction occurs just prior to the association of IRAK1 with 
caspase-4 in the signaling complex.  
The cellular interaction of caspase-4 and TRAF6 was further confirmed in a 
different system using tagged proteins transfected in an alternative cell type 293T. 
Transfected FLAG-TRAF6 was able to pull down endogenous as well as transfected 
myc-tagged caspase-4 in a co-immunoprecipitation experiment (Figure 4.11, lane 3), 
whereas in contrast myc-tagged caspase-1 failed to interact with TRAF6 (Figure 4.11, 
lane 5). Interestingly, the enzymatically inactive mutant of caspase-4 was still able to 
bind to TRAF6 efficiently (Figure 4.11, lane 6).  
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Figure 4.9 LPS induces endogenous caspase-4 to interact transiently with 
endogenous TRAF6 and IRAK1. (A) THP1 cells after treatment with LPS for various 
times were subjected to immunoprecipitation with TRAF6 or IRAK1 antibodies, and 
immuno-blotted with caspase-4 or TRAF6 or IRAK1 antibodies as indicated on the Western 
blots. (B) U937 monocytic cells after treatment with LPS for various times were subjected to 
immunoprecipitation with TRAF6 or IRAK1 antibodies, and immunoblotted with caspase-4 




4.7 Intact TRAF6-binding motif in caspase-4 important for TRAF6-
caspase-4 interaction  
Examination of caspase-4 reveals the presence of a putative TRAF6-binding 
motif (PPESGE) at aa 95-100, which probably lies in a surface location (Figure 4.10) 
in the protein (using the Swissmodel program (Guex and Peitsch, 1997; Peitsch et al., 
1995; Schwede et al., 2003)). Table 4.1A shows that PPESGE is similar to other 
TRAF6-binding sequences (Mansell et al., 2004), having an absolutely conserved 
proline and glutamic acid in the P-2 and P0 positions, as well as a well conserved 
glutamic acid in the P3 position. To examine the possibility that caspase-4 participates 
in TLR4 signaling by acting as a binding partner of TRAF6, I generated 1-3 
mutations in the TRAF6-binding site (TBS) of caspase-4 (A-C series, Table 4.1B) 
and assessed their ability to co-immunoprecipitate TRAF6. Consistent with the 
interactions of endogenous caspase-4 and TRAF6 (Fig. 4.9), FLAG-TRAF6 
interacted with both c-myc-tagged parental caspase-4 (Figure 4.11, lane 3) and active 
site mutant caspase-4 (Figure 4.11, lane 6). In contrast, caspase-4 mutants with single, 
double or triple mutations in the conserved residues of the putative TRAF6-binding 
motif failed to co-immunoprecipitate with FLAG-TRAF6 (Figure 4.11, lanes 7-9). As 
further evidence of the specificity of the TBS for TRAF6, I showed that the 
enzymatically inactive mutant of caspase-4 (Cys to Ser in the active site) was still 





Figure 4.10 TBS of caspase-4. Site PPESGE represented by dark blue, pink, green, red, 
light blue and purple, respectively. Protein modeling by email (Guex and Peitsch, 1997; 
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Figure 4.11 TRAF6-binding site in caspase-4 is essential for LPS-induced 
TRAF6-caspase4 interaction 293T cells were transfected with TRAF6-FLAG, caspase-4-
c-myc, active site mutant caspase-4-c-myc, control caspase-1-c-myc or TBS mutants (Table 
4.1B) in various combinations as shown in the key at top. 36 h after transfection, cells were 
treated with LPS for 10 min. and subjected to immunoprecipitation with FLAG antibody and 
immunoblotted with caspase-4 or c-myc antibody. Bottom two panels, input levels of 
transfected TRAF6-FLAG and caspase-c-myc proteins.  
 
 
4.8 Reconstitution of caspase-4 in the knocked down clones restores 
the original phenotype  
As the shRNA target site was located in the 3’ untranslated region of the 
caspase-4 mRNA, reconstitution was done with transient re-expression of the cDNA 
of caspase-4. The shRNA would not affect the expression of caspase-4, as there is no 









CLONES   WT    VC   TB     TB    TB    TC    TC    TC
+Caspase-4     -        -       -         +       -        -         +       -















Figure 4.12 Reconstitution of caspase-4 in the shRNA clones restores the NF-κB 
activity after LPS stimulation. Caspase-4 knocked down clones were transiently 
transfected with the cDNA of 1.wild-type caspase-4 or 2. TBS mutant caspase-4, along with 
the reporter plasmids, for 36 hours. The transfectants were treated with LPS for 4 hours and 
the NF-κB activity was quantified by luminometry.  
 
The caspase-4 knock-down clones were transfected transiently with either 
Caspase-4 cDNA or Caspase-4 cDNA with the TBS site mutated at three glutamic 
acid sites (TBS mutant C from the table 4.1) along with the NF-κB luciferase reporter 
and the control renilla reporter. The untransfected shRNA clones, TBand TC were 
unable to activate the NF-κB reporter to the same extent as the THP1 wild-type and 
vector control cells, just like in figure 4.6A. When caspase-4 was reconstituted by 
transfection, the NF-κB reporter activity was equal to the wild-type cells in the 
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shRNA clones. Reconstituting with the TBS mutant, ‘C’ was unable to restore the 
NF-κB activity in both the shRNA clones. 
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Figure 4.13 Reconstitution of caspase-4 in the KD clones restores the 
chemokines’ synthesis The caspase-4 knocked-down clones were transiently transfected 
with various caspase-4 constructs as indicated in the figures and subjected to LPS treatment 
for four hours. RNA was isolated and real-time quantification of the chemokines, IL-8, 
CCL4, CCL20 and IL-1β were done using superarray primers.  
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Reconstitution of caspase-4 in the shRNA clones also restored the synthesis of 
the chemokines, IL-8, CCL4, CCL20 and IL-1β back to wild-type levels. In the case 
of the active-site mutant of caspase-4, the rescue was even more impressive and was 
significantly higher than the wild-type levels, whereas the TBS mutant ‘C’ was 
unable to induce any chemokine synthesis. This experiment clearly showed that 







LPS, the cell wall component of infecting gram-negative bacteria stimulates 
TLR4 to signal through different transcription factors (notably NF-κB) to transcribe 
cytokines and chemokines like IL-8, IL-1β, MIP-1β and MIP-3α. These and other 
secreted proteins play important roles in innate immunity by eliciting inflammation 
and triggering the adaptive arm of immunity (Beutler et al., 2006). Human IL-8, the 
prototypical chemokine, has critical roles in acute inflammation, motogenesis, 
angiogenesis, tumorigenesis and metastasis (Mukaida et al., 1998; Xie, 2001). During 
inflammation MIP-1β, a member of the CC chemokine family, exhibits potent 
chemoattractant activity for T lymphocytes, NK cells and immature dendritic cells; 
moreover, MIP1β can block HIV-1 infection as both MIP1β and HIV-1 share the 
same receptor, CCR5 (Menten et al., 2002).   
By substantially knocking down caspase-4 expression with shRNAs, I showed 
that caspase-4 is required to produce a significant proportion of certain cytokines and 
chemokines (including IL-8 and MIP-1β) in the culture supernatant of a human 
monocytic cell line following LPS stimulation. It is established (Paik et al., 2003; 
Burke et al., 2003) and I confirmed that LPS-induced production of IL-8 and MIP-1β 
requires NF-κB-dependent transcription of their genes. IL-1β is another important 
cytokine that is activated by two distinct signals (Burns et al., 2003b; Mariathasan 
and Monack, 2007c); and the mechanisms that regulate its synthesis, maturation and 
secretion are of great interest in the context of various inflammatory disesases. As a 
component of the inflammasome, caspase-1 has an indispensable role in IL-1β 
maturation and here I report the involvement of caspase-4 as an additional protease 
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with a key role in the production of IL-1β. It is noteworthy that while caspase-1 is 
required for the cleavage and maturation of pro-IL-1β, caspase-4 acts much more 
upstream of caspase-1 by mediating the NF-κB-dependent transcription of the gene 
encoding IL-1β. 























Figure 4.14 Speculative model showing the position occupied by caspase-4 in 
LPS signaling. The LPS-induced interaction of caspase-4 and TRAF6 in a complex with 
IRAK1 stimulates the signaling pathway leading to IκBα degradation and NF-κB nuclear 
translocation that is required for the transcription and production of IL-8 and MIP-1β. The 
question mark between the caspase-4/TRAF6/IRAK1 complex and IKKβ indicates that the 
mechanisms by which caspase-4 contributes to NF-κB activation are not known. 
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My evidence suggests that the production of IL-8 and MIP-1β depend on 
caspase-4 acting upstream of LPS-induced, NF-κB-dependent transcriptional 
activation of their mRNAs (see model in Figure 4.14 above). At what point and by 
which mechanism could caspase-4 function between TLR4 and NF-κB? Ligand 
stimulation of TLR4 attracts the adaptor proteins MyD88 or MAL/TIRAP, which 
recruits and facilitates the activation of the receptor-associated kinase IRAK1 through 
its phosphorylation, leading to activation of TRAF6 (Akira et al., 2006; Kobayashi et 
al., 2004; Medzhitov, 2001). Subsequent TRAF6-mediated ubiquitylation (Deng et 
al., 2000; Wang et al., 2001) is required for the activation of TAK1 which associates 
with TAB-1, -2, and -3. The activated TAK1 complex phosphorylates the kinase 
IKKβ, which in turn phosphorylates IκB to facilitate its degradation resulting in 
activation of NF-κB required for transactivation of various cytokines (Akira and 
Takeda, 2004). Importantly, TRAF6 is required for LPS signaling in vivo. I showed 
that endogenous caspase-4 (but not caspase-1) interacts with TRAF6 through a well 
conserved TRAF6-binding motif that is known to be functionally important for 
TRAF6 interactions with other molecules, and for mediating NF-κB activation in 
various immune and non-immune cell types (Wu and Arron, 2003; Ye et al., 2002). 
Our findings together with these considerations strongly suggest that the TRAF6-
caspase-4 interaction may be necessary for LPS-induced NF-κB activation in human 
monocytic cells.  
Rescue experiments clearly demonstrated that the effects observed with the 
shRNA stable lines were due to the reduction in caspase-4 protein. The full length 
wild-type caspase-4 was able to restore the signaling via NF-κB activation and 
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synthesize the chemokines in the knocked down clones. The active site mutant was 
even more impressive by surpassing the levels of chemokines synthesized, compared 
to the wild-type and vector control cells. This might be due to the non-toxic nature of 
this active site mutant compared to the active-site intact WT caspase-4. TBS mutation 
in caspase-4 prevented the NF-κB signaling and subsequent chemokine synthesis, 
reconfirming the importance of TBS for downstream signaling upon LPS stimulation. 
It is interesting that caspases 3, 5, 7, 8, 10, 11 and 12 each have at least one 
potential TRAF6-binding site (TBS) (unpublished observations). This raises the 
question of whether any or all of these caspases are involved in some aspects of 
immune cell regulation through their interactions with TRAF6, a central mediator of 
signaling through several different TLRs (Lomaga et al., 1999). In fact, caspase-8 is 
involved in mediating T cell proliferation via TCR signaling, which is dependent on 
caspase-8 interacting with TRAF6 through a TBS (Bidere et al., 2006; He et al., 
2006). Human caspase-10 which is closely related to caspase-8 in homology and 
function (Rieux-Laucat et al., 2003) might therefore also utilize a TBS interaction for 
its signaling. Caspase-3 has been shown to have several roles in immune cell 
development (Santambrogio et al., 2005; Woo et al., 2003), and this could also 
potentially involve TRAF6 signaling. Caspases 5 and 11, with known roles in the 
inflammasome complex and LPS-induced cytokine up-regulation, respectively 
(Martinon et al., 2002; Wang et al., 1998), could be anticipated to have such a site for 
interactions with TRAF6 and subsequent signaling events. Only full-length human 
caspase-12, which is enzymatically inactive, has the TBS while the short truncated 
form present in the vast majority of the human population lacks this site. It has been 
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shown that full length inactive caspase-12 dampens endotoxin responsiveness through 
the production of fewer cytokines (Saleh et al., 2004; Saleh et al., 2006). This begs 
the question of whether the enzymatically inactive human caspase-12 might compete 
with caspase-4 for TRAF6-binding, thereby suppressing LPS-induced caspase-4-
dependent cytokine regulation and endotoxin responsiveness in a dominant-negative 
fashion.  
Caspase-8 has a role in B cell-mediated immunity and TCR-dependent T cell 
proliferation (Beisner et al., 2005; Lemmers et al., 2007; Su et al., 2005) and signals 
via its interaction with TRAF6 (Bidere et al., 2006; He et al., 2006). However, I 
believe it is unlikely that caspase-8 is also involved together with caspase-4 in LPS-
induced NF-κB activation and cytokine production in THP1 monocytic cells based on 
the following points. First, I showed that procaspase-8 protein was synthesized 
normally in the caspase-4 knockdown clones, which displayed defective NF-κB 
activation and cytokine production. Second, the cytokines TNFα (Fig. 4.3) and IFNβ 
(data not shown) were produced at normal levels in the caspase-4 knockdown cells in 
my study, but they were down-regulated in LPS-induced TLR4 signaling in caspase-8 
knockout cells (Lemmers et al., 2007). This seems to represent a situation where 
subtle differences in intracellular signaling components bring about specificity in 
TLR signaling. Caspase-1 is expressed in THP-1 cells and is crucial for pro-IL-1β 
processing and activation in vivo (Li et al., 1995). However, caspase-1 lacks a TBS, 
consistent with my observation that it fails to interact with TRAF6. This suggests that 
caspase-1 plays a role mainly in the LPS-induced processing of cytokines as a 
component of the inflammasome protein complex. 
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Enzymatically active caspase-8 is essential in TCR-mediated NF-κB 
activation (Bidere et al., 2006; Salmena et al., 2003), whereas in contrast the 
enzymatic activity of caspase-8 is dispensable for TNF-induced NF-κB activation (Su 
et al., 2005). We were not able to address the questions of (i) whether enzymatically 
active caspase-4 or (ii) the TRAF6-caspase-4 interaction, are required for LPS-
induced NF-κB activation and cytokine secretion. This is because the levels of 
endogenous pro-caspase-4 in THP1 cells are saturating, and transfection of pro-
caspase-4 or its various derived mutants did not stimulate further LPS-induced NF-κB 
activation and cytokine secretion (unpublished observations). This is not surprising 
given that only a small fraction of the pro-caspase-4 pool is likely to be recruited to 
TRAF6 in a signaling complex. The ideal experiment would involve reconstitution of 
caspase-4 in the shRNA knocked-down clones by using a plasmid expressing a full-
length caspase-4 with mutations in the shRNA recognition site. Use of TBS mutants 
in this scenario should permit determination of (i) whether enzymatically active 
caspase-4 and (ii) the TRAF6-caspase-4 interaction are required for LPS-induced NF-
κB activation and cytokine secretion. 
There are many other open questions. What are the partners and substrates of 
caspases 4 and 8 in immune cell signaling? Does caspase-4 participate in stimulating 
the E3 ubiquitin ligase function of TRAF6 that leads to NF-κB activation, or does it 
act on some other components of the signaling complex?  
Addressing the question of which is the closest human orthologue of murine 
caspase-11, my study reinforces the idea that both caspase-4 and caspase-5 have 
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caspase-11 as their ancestor (Lamkanfi et al., 2002; Martinon and Tschopp, 2007). 
Both caspases 4 and 5 share some characteristics of caspase-11, like inducibility after 
LPS treatment in the case of caspase-5 (Lin et al., 2000); and participation in innate 
immune responses in the case of both caspases 4 and 5 based on my results (Martinon 
and Tschopp, 2007). Yet caspase-4 also resembles caspase-12 in its ability to 
contribute to apoptosis induced by endoplasmic reticulum (ER)-mediated stress 
(Hitomi et al., 2004; Pelletier et al., 2006), though this remains controversial 
according to one study (Obeng and Boise, 2005). It seems, therefore, that human 
caspase-4 and caspase-5 have acquired additional diverse functions during their 
evolution. Thus, caspase-5 is involved in sensing endogenous danger signals via the 
inflammasome complex, for example leading to caspase-1 proteolytic processing and 
IL-1β and IL-18 production (Martinon et al., 2002), whereas caspase-4 participates in 
a classical receptor-dependent innate immune response to LPS, and possibly ER 
stress responses. The fact that caspase-4 regulates human IL-8, which also lacks an 
obvious homologue in mice (Mukaida et al., 1998) further reinforces this view of the 
relatively recent evolution of this class of caspases in mammals.  
Finally, caspase-8 deficiency leads to various immune-related diseases in 
different animal and human disease models (Chun et al., 2002); therefore, it would be 
interesting to examine other immune deficient diseases in humans to determine 
whether caspase-4 is down-regulated or mutated. 
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5. CHAPTER 5. Implications and future directions 
 
I showed that caspase-4 is involved in apoptosis caused by ER stress induced 
by polyglutamine aggregates. Therefore, caspase-4 might have a role in the 
pathogenesis of the group of diseases caused by the unstable CAG repeats. Hence, 
future studies need to be done on the targets/substrates of caspase-4 in ER stress to 
identify a more effective therapeutic target for these diseases. Caspase-9 was shown 
to be a downstream target of caspase-12 during ER stress-mediated apoptosis 
(Morishima et al., 2002). It would be important to investigate the caspase cascade in 
humans in ER stress by analyzing the possible activation of procaspase-9 and 
procaspase-3 by caspase-4. A protein called MAGE-3 (expressed in various tumors 
and not in normal tissues) binds procaspase-12 and suppresses the activity of caspase-
12. MAGE-3 has been detected in various human tumor cell lines (Morishima et al., 
2002). Hence, experiments could be designed to check whether MAGE-3 has any 
regulatory effect on caspase-4 in human cells during ER stress.  
I also showed that caspase-4-deficient cell lines are arrested in the G2/M 
phase to a greater extent upon ER stress compared to the cells expressing normal 
amounts of caspase-4. The UPR activation in mammals can either lead to cell death 
triggered by apoptotic effectors or survival by up-regulation of beneficial target genes 
encoding chaperones (Patil and Walter, 2001). The decision between these outcomes 
might be made during a cell cycle arrest that is generated during ER stress. It has 
been shown, at least in yeast, that the use of chemical ER stress reagents leads to 
accumulation of the cells in the G2/M phase (Bonilla and Cunningham, 2003).  
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Nevertheless, it has been shown in mammalian cells that mis-folded proteins and 
hence UPR could lead to cell cycle arrest due to a down-regulation of cyclin D1 
translation (Brewer et al., 1999; Brewer and Diehl, 2000). This translational 
regulation of cyclins may represent a ER checkpoint in which cell cycle progression 
is blocked under folding stress until ER homeostasis could be restored (Patil and 
Walter, 2001). This delay allows the cell to pause in the cell cycle to determine 
whether adaptation to stressful conditions, mediated by chaperones and other target 
genes, will be possible; and if not, to continue towards apoptosis. Therefore, targeting 
caspase-4 under specific neurological conditions involving polyglutamine aggregates 
induced UPR might allow the cells more recovery time to up-regulate the chaperone 
pathway and dispose of the unfavorable protein load. This might buy time for the cell 
to deal with and eliminate the toxic aggregates. Translational inhibition during the 
UPR is a general phenomenon mediated by an ER kinase, PERK. Like IRE-1, PERK 
phosphorylates eEF2α, resulting in down-regulation of protein synthesis. As 
demonstrated in PERK knockout cells, the protective effects are mainly due to the 
decrease in protein synthesis, which allows the cell more time to recover from the ER 
stress. Specific mechanisms allow efficient and selective translation of UPR target 
genes during this phase, which include transcriptional targets of ATF6 and IRE1 
(Figure 5.1) and which functions to eliminate the aberrant proteins, and prevent toxic 
accumulation of these proteins. Hence, cell cycle arrest might tip the balance in favor 
of survival if the cells are retained in the recovery phase longer. In such a scenario, 
targeting caspase-4, while accelerating the break-down of the toxic protein might 
prove a synergistic therapeutic strategy. 
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Figure 5.1 ER stress response decision between survival and apoptosis. Cell cycle 
arrest tips the balance by providing more time for the cells to recover from ER stress (Patil 
and Walter, 2001). License number: 1845690511702 
 
TLR activation is a double-edged sword (Liew et al., 2005), as it is necessary 
for initiating the innate immune response and enhancing adaptive immunity, but it 
also might trigger autoimmune, chronic inflammatory and infectious diseases. For 
example, sepsis, a severe disease, is caused by LPS, an agonist of TLR4. TLRs might 
also promote the pathogenesis of infections by hyper-induction of pro-inflammatory 
cytokines causing tissue damage; and it seems that most inflammatory and immune 
diseases will have a TLR component at some level. The ubiquitous nature of 
pathogens and stress proteins is such that if left unchecked the host will be 
overwhelmed by immune activation. This over stimulation could result from over 
activation of TLRs or dysregulation of endogenous TLR-signaling processes. Gaining 
a better understanding of the signaling mechanism and the players involved in this 
pathway should give us a better handle to manipulate and manage these diseases. 
Showing that caspase-4 is involved in TLR4 signaling initiated by LPS is a novel 
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discovery, and demonstrating the interaction with TRAF6 through its unique TBS in 
caspase-4 strongly suggests a basis for the mechanism of action. The diversity and 
specificity of TLR function is determined by the different intracellular signaling 
components and with this new knowledge, there is one more step to help in better 
understanding of the signaling pathways. 
Caspase-4 was shown to be involved in both neuronal ER stress-mediated 
apoptosis as well as in TLR4 signaling upon LPS stimulation in up-regulating 
inflammatory cytokines. I would like to propose a hypothesis about how the dual 
roles of caspase-4 could be interconnected in the physiological context - supported by 
recent evidence from literature. 
The UPR is vital for ER homeostasis and is the classically activated pathway 
upon ER stress. In lower organisms, the UPR involves up-regulating the adaptive 
responses to stress caused by unfolded proteins. In higher organisms, UPR is much 
more complex (Schroder and Kaufman, 2006). In mammals, firstly UPR involves up-
regulating chaperones and foldases to promote protein folding in the ER and 
remodeling the metabolic pathways required for asparagine-linked protein 
glycosylation with ER. Secondly, UPR also decreases the unfolded protein burden in 
the ER by stimulating  ER-associated degradation (ERAD) of slowly folding and 
incomplete proteins, thereby reducing the stress experienced by these cells (Patil and 
Walter, 2001). Thirdly, UPR also mediates an ‘alarm response’ in mammals by 
inducing NF-κB transactivation upon ER stress (Xu et al., 2005). This induces 
inflammation and up-regulation of immune response genes. The contribution of these 
genes to mounting an effective ER stress response has not yet been studied. This up-
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regulation of pro-inflammatory molecules, in spite of translational repression upon 
ER stress, is thought to be due to two mechanisms viz., leaky scanning or 
translational re-initiation (Schroder and Kaufman, 2006) 
Eukaryotic cells have three different mechanisms to deal with the 
accumulation of unfolded proteins in the ER: 1, Upon unfolded protein aggregation, 
translation initiation is inhibited by phosphorylating eIF2α; 2, Expression of proteins 
(chaperones) involved in enhancing folding and management is up-regulated by the 
UPR; 3, proteins lacking the proper tertiary structure are degraded by the ER-
Associated protein Degradation (ERAD) mechanism (van Laar et al., 2001). 
NF-κB activation upon ER stress is mediated by two pathways: 1, ERAD and 
2, eIF2α phosphorylation occurring during UPR. In the physiological context, there is 
the example of OxPAPC (Oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycero-
phosphorylcholine) accumulation in atherosclerotic lesions leading to ER stress and 
UPR resulting in an inflammatory response by upregulating IL-8, IL-6, MCP-1 etc 
(Gargalovic et al., 2006). Conditions associated with eIF2α phosphorylation during 
the UPR also directly activate NF-κB, and this phosphorylation is required for NF-κB 
activation (Deng et al., 2004). This ER stress-mediated NF-κB activation is 
attenuated both in PERK-/- cells and in eIF2α mutant cells. The physiological 
significance of this mechanism is not known.  
The development of atherosclerosis is associated with the production of pro-
inflammatory cytokines and chemokines by endothelial cells, leading to monocyte 
recruitment and accumulation in the sub endothelial space of arteries (Libby, 2002). 
Minimally oxidized low-density lipoprotein (LDL) and its primary bioactive 
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component, OxPAPC induce the chronic inflammatory response. OxPAPC causes ER 
stress and activation of the UPR pathway. This induction of UPR has been recently 
demonstrated in atherosclerotic lesions of apolipoprotein E knockout mice and in 
macrophages that accumulate excessive amounts of cholesterol, a hallmark of 
atherosclerosis (Feng et al., 2003; Zhou et al., 2005). It has been shown that ER stress 
activates the transcription factors ATF4 and XBP1, which directly participate in 
modulating immune responses. Here it would be interesting to check whether 
OxPAPC can up-regulate IL-8 and other inflammatory chemokines in caspase-4-
deficient lines. As I have shown that caspase-4 resides mainly in the ER and is 
activated upon ER stress together with its clear role in inflammatory cytokine 
signaling, an experiment to test the role of OxPAPC under caspase-4 deficient 
conditions might establish a link between OxPAPC and IL-8. I have shown clearly 
that caspase-4 is activated upon ER stress and also is able to induce pro-inflammatory 
cytokines. It is tempting to propose that OxPAPC and other ER stress activators like 
cholesterol and the cystic fibrosis mutant protein also induce the ER-resident caspase-
4 to activate the NF-κB and thereby induce proinflammatory chemokines, which is 
usually the secondary hallmark of these diseases.  
ERAD is an adaptive response by the cell when it encounters a misfolded 
protein. As soon as the ER encounters an aberrant protein, along with the UPR, it 
simultaneously activates the ERAD pathway to target and ubiquitinate the misfolded 
protein by transporting it to the cytosol and thus condemning it for destruction (Ismail 
and Ng, 2006). In most instances, aberrant substrates are identified and then targeted 
for ubiquitination in preparation for their destruction in the cytosol by the 
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proteosome. ERAD targets are selected by a quality control system within the ER 
lumen and are ultimately destroyed by the cytoplasmic ubiquitin-proteasome system. 
The spatial separation between substrate selection and degradation in ERAD requires 
substrate transport form the ER to the cytoplasm by a process termed dislocation (Vij 
et al., 2006).  
Recent studies in yeast showed that the processes of UPR and ERAD are 
functionally linked to one another. Cells lacking a functional ERAD constitutively 
activate the UPR, and many of the components of ERAD are under direct 
transcriptional control of the UPR. As UPR and ERAD are mostly conserved between 
yeast and mammals, there must be link between the UPR and ERAD in mammalian 
cells too. The question now is whether caspase-4 could serve as a part of this link by 
being activated upon ER stress to facilitate the ERAD pathway by its interaction with 
the mammalian multi-ubiquitin targeting factor, p97/ VCP (Valosin containing 
protein). 
VCP or p97 is a crucial cytoplasmic component of ERAD. It is a widely 
distributed AAA ATPase (known as cdc48 in yeast). Because ERAD substrates 
(misfolded proteins and aberrant aggregates) are fully ubiquitinataed before release 
into the cytosol, VCP might couple its ATPase activity to extraction of ubiquitylated 
substrates as they emerge from the ER and also function as an ubiquitin-specific 
segregase. VCP also physically interacts with several proteins that direct its function 
according to the context. VCP interacts with proteins required for degradation of 
ubiquitin fusion substrates, suggesting a close relationship with ubiquitin proteosome 
function. VCP also mediates apoptosis, the mechanism of which is unclear. Lack of 
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VCP resulted in inhibited ERAD and hence more ER stress (Wojcik et al., 2004). It 
also induced cell cycle arrest and subsequent apoptosis. VCP participates in the 
retrotranslocation of misfolded proteins from the ER for degradation by the cytosolic 
proteasomes. VCP interacts with these aberrant proteins and dislodges them from the 
ER.  
The most common disease causing protein folding mutation is deletion of 
phenylalanine at position 508 of the cystic fibrosis(CF) transmembrane regulator 
(CFTR), which results in a temperature-sensitive folding defect and premature 
degradation by ERAD (Ward et al., 1995). The absence of CFTR at the airway 
epithelial cell surface disrupts luminal hydration and is associated with an 
exaggerated immune response.  
Inhibiting VCP resulted in partial rescue of CFTR from degradation and hence 
suppression of ERAD. Several studies (Khan et al., 1995; Konstan et al., 1994) have 
shown that pulmonary inflammation may occur early in the course of CF. Hence 
selective VCP inhibition suppresses IL-8 levels along with ERAD. These studies also 
showed that neutrophil association with increased IL-8 in the airways is a prominent 
early feature of CF. VCP physically associates with IκBα and targets IκBα for 
degradation (Dai et al., 1998). The reduction in IL-8 levels in VCP knockdown could 
be explained by IκBα-mediated NF-κB inhibition. VCP itself is a major component 
of ER stress-induced apoptosis (Rao et al., 2004b). Therefore, VCP inhibition 
resulted in lack of apoptosis (Vij et al., 2006), showing that VCP is the integral 
component of ERAD and ER stress pathways. A summary of these findings is 
presented in figure 5.2 
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Figure 5.2. Diagrammatic summary of signaling by misfolded proteins.  
The information in the preceding paragraphs becomes interesting when 
considered in the light of a report (Rao et al., 2004b) that caspase-12 is a strong 
interacting partner of VCP under ER stress conditions, while weakly interacting with 
VCP under normal conditions in the cell . My work has shown that human caspase-4 is 
the functional orthologue of mouse caspase-12 under ER stress conditions, while being 
closer to murine caspase-11 during LPS-induced TLR4 signaling. It will be interesting 
to determine whether caspase-4 interacts with VCP under ER stress conditions in 
human cells, and whether caspase-4 deficiency suppresses the activation of VCP and 
the subsequent effects of ERAD and IL-8 induction. This could identify caspase-4 a 
significant connecting link between ER stress and the mechanism of pro-inflammatory 
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